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ABSTRACT: The C-H heteroarylation of benzaldehydes with indoles and pyrroles was realized using the benziodoxolone hyperva-
lent iodine reagents Indole- and Pyrrole- BX. Functionalization of the aldehyde C-H bond using either an ortho-hydroxy or amino 
directing group and catalyzed by an iridium or a rhodium complex allowed the synthesis of salicyloylindoles and (2-sulfonamino)ben-
zoylindoles, respectively with good to excellent  yields (74 to 98%). This new transformation could be carried out under mild condi-
tions (rt to 40 °C) and tolerated a broad range of functionalities, such as ethers, halogens, carbonyls or nitro groups. 
Indoles and pyrroles are ubiquitous in medicinal chemistry 
and natural products.1 Aryl indolyl ketones have attracted 
strong interest due to their interesting biological activities, in 
particular through interactions with the cannabinoid receptor.2 
Among them, the subclass in which the aryl moiety wears a hy-
droxy or an amino group in ortho position to the carbon-
ylshowed in addition diverse biological activities (Figure 1). 
Polymethoxylated indole derivatives 1 were cytotoxic against 
KB, MKN45, MCF-7 and colon HT-29 cells.3 3-(2-Aminoben-
zoyl)indole 2 led to VEGFR-2 inhibition.4 Furthermore, the sal-
icoyl pyrrole core is present in bhimamycins 3, antibiotic natu-
ral products isolated from the bacteria Streptomyces sp.5 
 
Figure 1. Synthetic and natural bioactive compounds with a 
2-hydroxy or 2-amino benzoyl indole or pyrrole core 
 
Due to their occurrence in biologically active compounds, the 
efficient synthesis of 3-benzoyl-indoles or -pyrroles is im-
portant. The most straightforward approach is based on the in-
nate reactivity of the heterocycles as nucleophiles combined 
with an electrophilic acylation reagent (Scheme 1a). However, 
Friedel-Crafts acylation of indoles under standard conditions 
usually leads to a complex mixture of mono-, di-acylated and 
oligomerization products due to their high electron density.1a 
This issue can be partially resolved by the introduction of elec-
tron-withdrawing protecting groups, the use of milder Lewis ac-
ids (Et2AlCl
6a-b, imidazolium chloroaluminate6c or ZrCl4
6d), re-
action with nitrilium salts7 or the use of hexafluoroisopropanol 
as solvent.8 Furthermore, the nucleophilicity of the heterocycles 
can be enhanced by conversion into Grignard or other organo-
metallic reagents, which can then be added directly to electro-
philes or used in metal-catalyzed cross-couplings.9 Recently, di-
rect C-H acylation catalyzed by transition metals has also been 
reported.10 The synthesis of 3-salicyloyl indoles was either not 
reported in these works, or required the protection/deprotection 
of the hydroxy group. Therefore, developing a more direct ac-
cess to these compounds would be highly desirable. In this re-
spect, only limited success has been achieved by the ring-open-
ing of chromones,11,12 1,3-dipolar cycloaddition, followed by 
decarboxylation,13 and alkylation of indoles with nitroolefins, 
followed by oxidative C-C bond cleavage.14 
Scheme 1. Classical vs Umpolung approaches for the syn-
thesis of 3-arylcarbonyl indoles 
 
As an alternative strategy, we envisaged an Umpolung path-
way involving a nucleophilic acyl metal intermediate generated 
 via Csp2-H activation of an aldehyde
15 and an electrophilic in-
dole (Scheme 1b). Concerning the nucleophilic partners, ben-
zaldehydes substituted with oxygen or nitrogen heteroatoms in 
ortho position are privileged substrates, as the directing group 
is necessary for C-H activation under mild conditions.15a As 
electrophilic partners, we considered hypervalent iodine(III) re-
agents, which have been extensively used as Umpolung rea-
gents in numerous transformations.16 In fact, both aryl iodoni-
ums and ethynylbenziodoxolones (EBX) have been used to in-
troduce phenyl or alkyne derivatives via cross-coupling on sa-
licylaldehydes.17 However, there are only few methods for the 
synthesis of indole-and pyrrole-based iodonium salts.18 Further-
more, due to their limited stability, these compounds have 
found only very limited use in transition metal catalysis. Re-
cently, our's and Yoshikai's group reported the synthesis of 
bench-stable indole- and pyrrole-benziodoxolones (indoleBX 
and pyrroleBX).19 We further demonstrated that the new indole- 
and pyrrole- BX reagents could be used for directed C-H func-
tionalization with rhodium or ruthenium catalysts, whereas io-
donium salts were not successful.19a Herein, we report the C-H 
functionalization of 2-hydroxy and 2-amino benzaldehydes de-
rivatives with Indole- and Pyrrole-BX reagents using either irid-
ium or rhodium catalysts to give access to important indole and 
pyrrole building blocks. 
We initiated the studies on C-H indolation with the optimiza-
tion of the reaction conditions for the coupling of salicylalde-
hyde 4a with Me-indoleBX 5a (Table 1). While [RhCp*Cl2]2 as 
catalyst gave only traces of the desired product 6a (Table 1, en-
try 1), we were pleased to see that the use of [IrCp*Cl2]2 led to 
formation of 6a in excellent 91% yield in the presence of cesium 
acetate at room temperature (Table 1, entry 2). This is the first 
example of the use of an iridium catalyst with IndoleBX rea-
gents. Furthermore, the reaction did not require any particular 
precautions concerning the presence of water or oxygen. Com-
plete conversion was reached after 10 minutes at room temper-
ature. Cheaper potassium acetate could also be used to give 90% 
yield of the ketone product 6a (Table 1, entry 3). Variation of 
the amount of KOAc revealed that a superstoichiometric 
amount was not necessary (Table 1, entry 4). However, the yield 
decreased when the base was used in a substoichiometric quan-
tity (Table 1, entry 5) and without base only 56% yield was ob-
tained, even if full conversion was still observed (Table 1, entry 
6). Finally, we were able to reduce the catalyst loading to 1 mol 
% without significant change in yield, demonstrating the ro-
bustness of the catalyst (Table 1, entry 7). A scale-up to 1.20 
mmol allowed us to decrease the iridium catalyst loading to 0.5 
mol %, giving 93% yield of 6a in the same reaction time (Table 
1, entry 8). Control experiments indicated that the transition 
metal complex is essential for the reaction.20 When 3-bromo-1-
methylindole and 3-iodo-1-methylindole were used as reagents, 
the desired compounds were obtained in 59% and 53% yield 
respectively, but only after heating over night at 80 °C.20 This 
result further highlights the exceptional reactivity of IndoleBX 
reagents. 
The scope of the reaction was then studied (Scheme 2). The 
effect of substituents in the para position to the hydroxy group 
was examined first (6a-i). In terms of electronic effect, both 
electron-donating alkyl and ether groups (6b and 6c) and elec-
tron-withdrawing halogens, aldehyde and nitro groups (6d-i) 
were well tolerated. The exclusive formation of product 6h 
starting from a bis-formylated benzene confirmed the require-
ment of a directing group for C-H activation.21 In term of sub-
stitution pattern of the benzene ring, a methoxy group was tol-
erated also in all other positions (6j-l).  
Table 1. Optimization studiesa 
 
entry catalyst base (equiv) yield (%)b 
1 [RhCp*Cl2]2 CsOAc (1.2) tracesc 
2 [IrCp*Cl2]2 CsOAc (1.2) 91 
3 [IrCp*Cl2]2 KOAc (1.2) 90 
4 [IrCp*Cl2]2 KOAc (1.0) 90 
5 [IrCp*Cl2]2 KOAc (0.5) 86 
6 [IrCp*Cl2]2 - 56 
7 [IrCp*Cl2]2 KOAc (1.0) 94d 
8 [IrCp*Cl2]2 KOAc (1.0) 93e 
aReactions conditions: 4a (0.05 mmol), 5a (0.05 mmol), 
[IrCp*Cl2]2 (3 mol %), base, methanol (0.5 mL) at rt for 10 min. 
bIsolated yield after column chromatography. cReaction performed 
at 80 °C. d[IrCp*Cl2]2 (1 mol %). eYield at a 1.20 mmol scale with 
0.5 mol % [IrCp*Cl2]2. 
Scheme 2. Ir(III)-catalyzed C-H indolation of 2-hy-
droxybenzaldehydes.a,b 
 
aReactions conditions: 4 (0.15 mmol), 5 (0.15 mmol), 
[IrCp*Cl2]2 (1 mol %), KOAc (0.15 mmol), methanol (1.5 mL) at 
rt for 10 min. bIsolated yield after column chromatography. c93% 
 yield for a reaction at 1.20 mmol scale. d30 min. e1 h. fReaction 
performed at 50 °C for 2 h. gReaction performed at 70 °C for 2 h. 
A longer reaction time of 30 minutes was observed only in 
case of 2-hydroxy-6-methoxybenzaldehyde 4l to give 6l in 86% 
yield. Alkyl-substituted products 6m and 6n were also obtained 
in good yields. Naphthalene and estrone-derivatives 6o and 6p 
were isolated in excellent 91% and 98% yields respectively. 
Pentacyclic compound 6q wearing a carbazole heterocycle was 
obtained in 90% yield. Modification of the hypervalent iodine 
reagent was then investigated. Changing the N-substitution 
from methyl to pentyl or butenyl delivered indoles 6r-u. The 
corresponding O-methylated compounds are reported synthetic 
cannabinoids.22 A bromo substituent on the benzene ring was 
well tolerated (6v).The N-H free compound 6w could be also 
obtained with complete regioselectivity in 85% yield. For prod-
ucts 6u and 6w, it was necessary to perform the reaction at 70 
°C to reach full conversion. Importantly, the method could be 
extended to the synthesis of pyrrole 6x using a PyrroleBX as 
reagent.  
We then turned to the use of nitrogen-based directing groups 
for the activation of the aldehyde C-H bond. In the case of 2-
aminobenzaldehyde 7a bearing a N-tosyl directing group a 
Rh(III) dimer catalyst proved to be as effective as the Ir(III) cat-
alyst (Scheme 3), in contrast to what had been observed with 
salicylaldehyde 4a (Table 1). The reaction was best run in 
MeOH at 40 °C during 4 h.20 Several N-sulfonyl groups (tosyl, 
para-nosyl and mesyl) could be used to direct the C-H function-
alization, giving products 8a-c in 80-88% yield. In contrast, a 
N-boc directing group was inefficient for this transformation 
(result not shown). The reaction could be perform in the pres-
ence of a chlorine atom on the phenyl ring affording the product 
8d with 91% yield. The thiophene-derivatived compound 8e 
was isolated in an excellent 90% yield. This rhodium-catalyzed 
reaction also tolerated a N-butenyl substituent or a bromo group 
on the indole benzene ring, giving the desired products 8f and 
8g in 79% and 82% yields, respectively. 
Scheme 3. Rh(III)-catalyzed C-H indolation of 2-sulfonyla-
minobenzaldehydes.a,b 
  
aReactions conditions: 7 (0.15 mmol), 5 (0.15 mmol), 
[RhCp*Cl2]2 (1 mol %), KOAc (0.15 mmol), methanol (1.5 mL) at 
40 °C for 4 h. bIsolated yield after column chromatography. c80% 
yield for a reaction at 0.80 mmol scale. 
The directing groups were not only useful for allowing C-H 
functionalization under mild conditions (see Supporting Infor-
mation for a mechanism proposal),15a,17c they also served as han-
dles for further modifications (Scheme 4). For example, phenol 
6a was quantitatively transformed into the corresponding tri-
flate 9 by reaction with triflic anhydride. Suzuki-Miyaura cross-
coupling with phenyl boronic acid gave then biphenyl deriva-
tive 10 in 89% yield over 2 steps. Alternatively, the directing 
group could be fully removed by a palladium-catalyzed reduc-
tion of the triflate to furnish 3-benzoylindole 11. From N-sul-
fonylphenyl substituted ketones 8a and 8b, an iodine-mediated 
oxidative C-2 amination generated tetracyclic indolo-
[2,3b]quinolinone 12a and 12b in quantitative yield for tosyl 8a 
and 89% yield for nosyl 8b.22 The nosyl protecting group was 
synthetically especially useful, as it could be removed in pres-
ence of thiophenol, either on the cyclized product 12b or the 
indolation product 8b to give the N-H free heterocycles 13 and 
14. 
Scheme 4. Product modifications 
 
In summary, we have reported the first example of aldehyde 
C-H heteroarylation giving highly useful indole and pyrrole 
building blocks. The reaction proceeded under mild, neutral 
conditions using either an alcohol or a sulfonylamide directing 
group with an iridium or a rhodium catalyst, respectively and 
the cyclic hypervalent iodine reagents Indole- and PyrroleBX. 
This represented also the first use of an iridium catalyst with 
Indole- and PyrroleBX as reagents. As the reaction tolerated a 
broad range of functional groups and the obtained versatile in-
dole and pyrrole building blocks could be easily further modi-
fied, the method is expected to be highly useful in synthetic and 
medicinal chemistry. 
Detailed optimization tables, experimental procedures, analytical 
data for all compounds and copies of the NMR spectra for new 
compounds are available free of charge on the ACS Publications 
website.  
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1. General methods 
 
All reagents and solvents were purchased from commercial sources ABCR, Acros, Sigma Aldrich, Fluka, 
VWR, Aplichem or Merck and used as such unless stated otherwise. Chromatographic purification was 
performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å. TLC was performed on 
Merck silica gel 60 F254 TLC glass plates and visualized with UV light, permanganate stain or 
phosphomolybdic acid stain. Melting points were measured on a calibrated Büchi B-540 melting point 
apparatus using open glass capillaries. 1H-NMR spectra were recorded on a Bruker DPX-400 400 MHz 
spectrometer in CDCl3, CD2Cl2, DMSO-d6, CD3OD; all signals are reported in ppm with the internal 
chloroform signal at 7.26 ppm, the internal CD2Cl2 signal at 5.32 ppm, the internal DMSO signal at 2.50 
ppm or the internal methanol signal at 3.30 ppm as standard. The data is being reported as (s = singlet d = 
doublet t = triplet q = quadruplet quint = quintet m = multiplet or unresolved bs = broad signal, coupling 
constant(s) in Hz, integration, interpretation). 19F-NMR spectra were recorded on a Bruker DPX-400 376 
MHz spectrometer in CDCl3. 13C-NMR spectra were recorded with 1H-decoupling on a Bruker DPX-400 
101 MHz spectrometer in CDCl3, CD2Cl2, DMSO-d6, CD3OD; all signals are reported in ppm with the 
internal chloroform signal at 77.2 ppm, the internal CD2Cl2 signal at 54.0 ppm, the internal DMSO signal 
at 39.5 ppm or the internal methanol signal at 49.0 ppm as standard. Infrared spectra were recorded on a 
JASCO FT-IR B4100 or a Brucer Alpha-P spectrophotometer with an ATR device and a ZnSe prisma and 
are reported as cm-1 (w = weak, m = medium, s = strong, br = broad). High resolution mass spectrometric 
measurements were performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS 
(ESI) Q-TOF Ultima API. 
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2. Syntheses of starting materials 
 
2. 1. General procedure A for the synthesis of iridium and rhodium complexes 
 
 
 
Following a reported procedure,1 the metal trichloride hydrate (1.00 equiv) and 1,2,3,4,5-
pentamethylcyclopenta-1,3-diene (1.50 equiv) were solubilized in MeOH [0.2 M]. The mixture was stirred 
at 140 °C for 3 min under microwave irradiation. The mixture was washed three times with pentane (same 
volume as MeOH). Et2O (same volume as MeOH) was added, the precipitate was isolated, washed twice 
with Et2O and dried under reduced pressure to afford the title compound.  
 
Pentamethylcyclopentadienyliridium (III) dichloride dimer [IRCp*Cl2]2 
 
Following general procedure A and starting from commercially available iridium 
(III) chloride hydrate (245 mg, 0.820 mmol), pentamethylcyclopentadienyl-
iridium (III) dichloride dimer (264 mg, 0.320 mmol, 39% yield) (CAS number 
12354-84-6) was obtained as an orange solid. 
 
1H NMR (400 MHz, CDCl3) δ 1.62 (s, 30H).2 
 
 
 
Pentamethylcyclopentadienylrhodium (III) chloride dimer [RhCp*Cl2]2 
 
Following general procedure A and starting from commercially available 
rhodium (III) chloride hydrate (385 mg, 1.84 mmol), pentamethylcyclopenta-
dienylrhodium (III) dichloride dimer (382 mg, 0.590 mmol, 67% yield) (CAS 
number 12354-85-7) was obtained as a red solid. 
 
1H NMR (400 MHz, CDCl3) δ 1.59 (s, 30H). 
  
                                                   
1 Tönnemann, J.; Risse, J.; Grote, Z.; Scopelliti, R.; Severin, K. Eur. JIC 2013, 4558−4562. 
2 Vázquez-Villa, H.; Reber, S.; Ariger, M. A.; Carreira, E. M. Angew. Chem. Int. Ed. 2011, 50 , 8979 –8981. 
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2.2. Procedures for the synthesis of 2-hydroxybenzaldehydes 
 
The reagents 4a-k, 4m, 4n and 4o are commercially available. 
 
2-Hydroxy-6-methoxybenzaldehyde (4l) 
Aluminium trichloride (2.00 g, 15.0 mmol, 3 .00 equiv.) were suspended in dry DCM (20 
mL) under Ar. Commercially available 2,6-dimethoxybenzaldehyde (831 mg, 5.00 mmol, 
1.00 equiv) was solubilized in dry DCM (20 mL) under Ar and added to the solution at rt. 
The mixture was stirred 24 h at rt and quenched with aqueous 1 M HCl solution (20 
mL). The two layers were separated and the aqueouse layer was extracted three times with 
DCM (20 mL). The organic layers were combined, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel (Pentane/EtOAc 4:1) 
affording the title compound 4l (210 mg, 1.38 mmol, 27% yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 11.98 (s, 1H, OH), 10.33 (s, 1H, CHO), 7.41 (t, J = 8.4 Hz, 1H, HAr), 6.52 
(d, J = 8.5 Hz, 1H, HAr), 6.37 (d, J = 8.3 Hz, 1H, HAr), 3.89 (s, 3H, OCH3). 13C NMR (101 MHz, CDCl3) δ 
194.5, 163.8, 162.6, 138.6, 111.0, 110.0, 101.1, 56.0. Spectra data matched with the values reported in 
literature.3 
  
(8R,9S,13S,14S)-3-Hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta-
[a]phenanthrene-2-carbaldehyde (4p) 
Following a reported procedure,4 commercially available estrone (243 mg, 
0.899 mmol, 1.00 equiv), magnesium chloride (257 mg, 2.70 mmol, 3.00 
equiv) and formaldehyde (81.0 mg, 2.70 mmol, 3.00 equiv.) were suspended 
in dry THF (9 mL) under Ar. Triethylamine (0.50 mL, 3.6 mmol, 4.0 equiv.) 
was added to the solution and the mixture was stirred 2 h at reflux. The 
solution was quenched with aqueous 4 M HCl solution (10 mL) and extracted 
three times with EtOAc (10 mL). The organic layers were combined, dried over MgSO4 and concentrated 
under reduced pressure. The crude product was purified by column chromatography on silica gel 
(Pentane/EtOAc 4:1) affording the title compound 4p (180 mg, 0.602 mmol, 67% yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 10.77 (s, 1H, OH), 9.79 (s, 1H, CHO), 7.41 (s, 1H, HAr), 6.69 (s, 1H, HAr), 
2.97-2.85 (m, 2H, Haliph), 2.50 (dd, J = 18.9, 8.6 Hz, 1H, Haliph), 2.40 (s, 1H, Haliph), 2.27-1.96 (m, 5H, Haliph), 
1.67-1.38 (m, 6H, Haliph), 0.91 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 196.2, 159.4, 147.8, 132.2, 
130.6, 119.1, 117.1, 50.5, 48.0, 43.5, 38.0, 35.9, 31.5, 30.1, 26.2, 25.9, 21.7, 13.9. Spectra data matched 
with the values reported in literature.4 
 
4-Hydroxy-9H-carbazole-3-carbaldehyde (4q) 
Following a reported procedure,5 phosphoryl trichloride (0.400 mL, 4.30 mmol, 1.20 equiv.) was slowly 
added to DMF (2 mL) at 15 °C under Ar. 9H-carbazol-4-ol (655 mg, 3.58 mmol, 
1.00 equiv.) was solubilized in DMF (4 mL) and slowly added at rt. The mixture 
was stirred 1 h at 35 °C and poured into crush ice and treated with 1 M NaOH (5 
mL). The mixture was extracted three times with EtOAc (10 mL). The organic 
layers were combined, dried over MgSO4 and concentrated under reduced pressure. 
The crude product was purified by column chromatography on silica gel 
(Pentane/EtOAc 7:3) and washed with Et2O affording the title compound 4q (430 mg, 2.04 mmol, 57% 
yield) as a grey solid. 
1H NMR (400 MHz, CDCl3) δ 12.42 (s, 1H, OH), 9.88 (s, 1H, CHO), 8.39 (bs, 1H, NH), 8.37 (d, J = 7.8 
Hz, 1H, HAr), 7.50 (d, J = 8.4 Hz, 1H, HAr), 7.45 (d, J = 3.9 Hz, 2H, HAr), 7.35 (m, 1H, HAr), 7.02 (d, J = 
8.4 Hz, 1H, HAr). 13C NMR (101 MHz, CDCl3) δ 195.2, 160.4, 145.4, 138.8, 131.5, 126.0, 123.4, 122.9, 
121.5, 113.7, 111.5, 110.7, 103.6. Spectra data differs slightly from the values reported in literature.5   
                                                   
3 Yoshioka, E.; Kohtani, S.; Miyabe, H. Org. Lett. 2010, 12, 1956-1959. 
4 Akselsen, Ø. W.; Hansen, T. V. Tetrahedron 2011, 67, 7738-7742. 
5 Bhosale, S. M.; Momin, A. A.; Kusurkar, R. S. Tetrahedron 2012, 68, 6420-6426. 
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2.3. General procedure B for the synthesis of N-(2-formylphenyl)sulfonamides 
 
 
 
(2-aminophenyl)methanol (1.00 equiv) and the corresponding sulfonyl chloride (1.10 equiv) were 
solubilized in CHCl3 [0.4 M]. Pyridine (1.20 equiv) was added to the solution and the mixture was stirred 
overnight at room temperature. The mixture was concentrated under reduced pressure. The residue was 
taken up in EtOAc (30 mL) and washed three times with an aqueous 4 M HCl solution (15 mL) and once 
with a NaHCO3 solution (15 mL). The organic layer was dried over magnesium sulfate dehydrate, filtered 
and concentrated under reduced pressure. The desired N-(2-(hydroxymethyl)phenyl)sulfonamide, obtained 
without further purification, was solubilized in DCM [0.3 M]. Pyridinium chlorochromate (1.50 equiv) was 
added in one portion and the mixture was stirred at room temperature for 2 hours. The solution was filtered 
on a 5 cm pad of silica gel then washed with DCM (100 mL). The filtrate was concentrated under reduced 
pressure. The residue was purified by recrystallization in EtOH/CHCl3 4:1 to afford the title compound. 
 
N-(2-Formylphenyl)4-methylbenzenesulfonamide (7a) 
 
Following general procedure B and starting from commercially available (2-
aminophenyl)methanol (0.75 g, 6.1 mmol), N-(2-formylphenyl)4-
methylbenzenesulfonamide 7a (1.40 g, 5.08 mmol, 83% yield) (CAS number 6590-
65-4) was obtained as a white solid. 
1H NMR (400 MHz, CDCl3) δ 10.79 (s, 1H, NHTs), 9.83 (s, 1H, CHO), 7.77 (d, J = 
8.3 Hz, 2H, Htolyl), 7.69 (d, J = 8.4 Hz, 1H, HAr), 7.59 (dd, J = 7.7, 1.5 Hz, 1H, HAr), 
7.51 (td, J = 8.6, 8.1, 1.6 Hz, 1H, HAr), 7.24 (d, J = 8.0 Hz, 2H, Htolyl), 7.16 (td, J = 
7.6, 0.9 Hz, 1H, HAr), 2.37 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 195.1, 144.3, 140.1, 136.5, 136.2, 136.0, 129.9, 127.4, 123.1, 122.0, 117.9, 
21.7. Spectra data matched with the values reported in literature.6 
 
N-(2-Formylphenyl)4-nitrobenzenesulfonamide (7b) 
 
Following general procedure B and starting from commercially available (2-
aminophenyl)methanol (0.75 g, 6.1 mmol), N-(2-formylphenyl)4-
nitrobenzenesulfonamide 7b (1.20 g, 3.92 mmol, 64% yield) (CAS number 
601481-97-4) was obtained as a yellow solid. 
1H NMR (400 MHz, CDCl3) δ 10.92 (s, 1H, NHNs), 9.83 (s, 1H, CHO), 8.29 (d, 
J = 8.9 Hz, 2H, Hnosyl), 8.06 (d, J = 8.9 Hz, 2H, Hnosyl), 7.73 (d, J = 8.4 Hz, 1H, 
HAr), 7.64 (dd, J = 7.6, 1.5 Hz, 1H, HAr), 7.59-7.55 (m, 1H, HAr), 7.25 (td, J = 7.6, 
0.8 Hz, 1H, HAr). 
13C NMR (101 MHz, CDCl3) δ 195.3, 150.5, 145.1, 139.0, 136.5, 136.2, 128.7, 124.6, 124.2, 122.4, 118.3. 
1H NMR Spectra data matched with the values reported in literature.5 
  
                                                   
6 Hechavarría Fonseca, M.; Eibler, E.; Zabelb, M.; König, B. Tetrahedron: Asymmetry 2003, 14, 1989-1994. 
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N-(2-Formylphenyl)methanesulfonamide (7c) 
 
Following general procedure B and starting from commercially available (2-
aminophenyl)methanol (0.75 g, 6.1 mmol), N-(2-formylphenyl)methanesulfonamide 7c 
(0.680 g, 3.42 mmol, 56% yield) (CAS number 94532-99-7) was obtained as a white solid. 
1H NMR (400 MHz, CDCl3) δ 10.60 (s, 1H, NHMs), 9.92 (s, 1H, CHO), 7.73 (t, J = 7.6 Hz, 
2H, HAr), 7.62 (t, J = 7.9 Hz, 1H, HAr), 7.28-7.24 (m, 1H, HAr), 3.10 (s, 3H, CH3). 13C NMR 
(101 MHz, CDCl3) δ 195.2, 140.3, 136.6, 136.3, 123.1, 121.7, 117.1, 40.5. Spectra data 
matched with the values reported in literature.7 
 
N-(4-Chloro-2-formylphenyl)-4-methylbenzenesulfonamide (7d) 
 
Following general procedure B and starting from commercially available (2-
amino-5-chlorophenyl)methanol (236 mg, 1.50 mmol), N-(4-chloro-2-
formylphenyl)4-methylbenzenesulfonamide 7d (416 mg, 1.34 mmol, 89% 
yield) (CAS number 34159-03-0) was obtained as a white solid. 
1H NMR (400 MHz, CDCl3) δ 10.63 (s, 1H, NHTs), 9.77 (s, 1H, CHO), 7.75 
(d, J = 8.3 Hz, 2H, Htolyl), 7.68 (d, J = 8.9 Hz, 1H, HAr), 7.55 (d, J = 2.5 Hz, 1H, 
HAr), 7.46 (dd, J = 8.9, 2.5 Hz, 1H, HAr), 7.25 (d, J = 8.3 Hz, 2H, Htolyl), 2.37 (s, 
3H, CH3). 13C NMR (101 MHz, CDCl3) δ 193.9, 144.6, 138.6, 136.2, 135.8, 135.3, 130.0, 128.5, 127.4, 
122.9, 119.7, 21.7. Spectra data matched with the values reported in literature.8 
 
N-(2-Formylthiophen-3-yl)-4-methylbenzenesulfonamide (7e) 
 
 
Methyl 3-amino-2-thiophenecarboxylate (1.00 equiv) and tosyl chloride (1.10 equiv) were solubilized in 
CHCl3 [0.4 M]. Pyridine (1.20 equiv) was added to the solution and the mixture was stirred overnight at 
room temperature. The mixture was concentrated under reduced pressure. The residue was taken up in 
EtOAc (30 mL) and washed three times with an aqueous 4 M HCl solution (15 mL) and once with a NaHCO3 
solution (15 mL). The organic layer was dried over magnesium sulfate dehydrate, filtered and concentrated 
under reduced pressure. In a flame-dried flask, the methyl 3-(4-methylphenylsulfonamido)thiophene-2-
carboxylate, obtained without further purification, was solubilized in dry THF [0.2 M] under Ar. DIBAL-H 
(4.00 equiv.) was added to the solution at -78 °C and the mixture was stirred 4 h until 0 °C. The mixture 
was quenched with a saturated aqueous solution of Rochelle’s salt (10 mL) and filtered over Celite. The 
layers were separated and the aqueous layer was extracted three times with EtOAc (20 mL). The organic 
layer was dried over magnesium sulfate dehydrate, filtered and concentrated under reduced pressure. The 
N-(2-(hydroxymethyl)thiophen-3-yl)-4-methylbenzenesulfonamide, obtained without further purification, 
was solubilized in dry DCM [0.2 M]. Pyridinium chlorochromate (1.50 equiv) was added in one portion and 
the mixture was stirred at room temperature for 2 hours. The solution was filtered on a 5 cm pad of silica 
gel then washed with DCM (100 mL). The filtrate was concentrated under reduced pressure to afford the 
title compound 7e (60% yield over 3 steps). 1H NMR (400 MHz, CDCl3) δ 10.14 (s, 1H, NHTs), 9.59 (s, 
1H, CHO), 7.76 (d, J = 6.5 Hz, 2H, Htolyl), 7.65-7.58 (m, 1H, Hthiophenyl), 7.47-7.38 (m, 1H, Hthiophenyl), 7.27 
(d, J = 5.7 Hz, 2H, Htolyl), 2.39 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 184.0, 144.6, 143.8, 136.4, 
136.4, 130.0, 127.2, 121.0, 120.7, 21.7. Spectra data matched with the values reported in literature.9 
                                                   
7 Nemoto, T.; Fukuda, T.; Hamada, Y. Tetrahedron Letters 2006, 47, 4365-4368. 
8 Theeraladanon, C.; Arisawa, M.; Nishida, A.; Nakagawa, M. Tetrahedron 2004, 60, 3017-3035. 
9 Mu, D.; Wang, X.; Chen, G.; He, G. J. Org. Chem. 2017, 82, 4497−4503. 
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2.4. General procedure C for the synthesis of N-alkylindoles 
 
 
 
Sodium hydride (60% in mineral oil, 1.10 equiv) was suspended in DMF [0.6 M]. N-H-indole (1.00 equiv) 
was solubilized in DMF [1.0 M] and added to the suspension at 0 °C. The mixture was stirred at rt for 30 
min. Bromoalkyl or TMSCl (1.50 equiv) was diluted in DMF [3.0 M] and added to the solution at 0 °C. The 
mixture was stirred at rt for 1 hour. The solution was quenched with water (20 mL) and extracted three times 
with EtOAc (10 mL). The organic layers were combined, dried over MgSO4 and concentrated under reduced 
pressure. The liquid was filtered through a 5 cm pad of silica with 100% pentane or Et2O to afford the title 
compound. 
 
1-Pentyl-1H-indole (15b) 
 
Following general procedure C and starting from commercially available indole (1.32 g, 
11.3 mmol), 15b (2.11 g, 11.3 mmol, quantitative yield) (CAS number 59529-21-4) was 
obtained as a colorless liquid. 
1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 7.9 Hz, 1H, HAr), 7.37 (d, J = 8.2 Hz, 1H, HAr), 
7.23 (t, J = 7.6 Hz, 1H, HAr), 7.14-7.10 (m, 2H, HAr), 6.51 (d, J = 3.0 Hz, 1H, HAr), 4.13 (t, 
J = 7.2 Hz, 2H, NCH2), 1.86 (quint, J = 7.2 Hz, 2H, Haliph), 1.42-1.20 (m, 4H, Haliph), 0.91 (t, J = 6.9 Hz, 3H, 
CH3). 
13C NMR (101 MHz, CDCl3) δ 136.1, 128.7, 127.9, 121.4, 121.0, 119.3, 109.5, 100.9, 46.5, 30.1, 29.3, 
22.5, 14.1. Spectra data matched with the values reported in literature.10 
 
1-(But-3-en-1-yl)-1H-indole (15c) 
 
Following general procedure C and starting from commercially available indole (1.54 g, 13.1 
mmol), 15c (0.39 g, 2.3 mmol, 17%) (CAS number 46169-71-5) was obtained as a colorless 
liquid. 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 7.9 Hz, 1H, HAr), 7.36 (d, J = 8.2 Hz, 1H, HAr), 
7.24-7.20 (m, 1H, HAr), 7.13-7.09 (m, 2H, HAr), 6.49 (d, J = 3.1 Hz, 1H, HAr), 5.80 (ddt, J = 
17.1, 10.2, 6.9 Hz, 1H, CH=CH2), 5.11-5.05 (m, 2H, CH=CH2), 4.20 (t, J = 7.2 Hz, 2H, NCH2), 2.59 (q, J 
= 6.9 Hz, 2H, NCH2CH2). 
13C NMR (101 MHz, CDCl3) δ 136.0, 134.8, 128.7, 127.9, 121.5, 121.1, 119.4, 117.5, 109.5, 101.2, 46.1, 
34.7. Spectra data matched with the values reported in literature.11 
 
5-Bromo-1-methyl-1H-indole (15d) 
 
Following general procedure C and starting from commercially available 5-bromoindole 
(0.59 mg, 3.0 mmol), 15d (630 mg, 3.00 mmol, quantitative yield) (CAS number 10075-
52-2) was obtained as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 1.6 Hz, 1H, HAr), 7.30 (dd, J = 8.7, 1.8 Hz, 1H, 
HAr), 7.19 (d, J = 8.7 Hz, 1H, HAr), 7.05 (d, J = 3.1 Hz, 1H, HAr), 6.43 (d, J = 3.1 Hz, 1H, 
HAr), 3.78 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 135.5, 130.2, 130.1, 124.4, 123.4, 112.8, 110.8, 100.6, 33.1. 
Spectra data matched with the values reported in literature.12 
                                                   
10 Banister, S. D.; Wilkinson, S. M.; Longworth, M.; Stuart, J.; Apetz, N.; English, K.; Brooker, L.; Goebel, C.; Hibbs, D. E.; Glass, M.; Connor, 
M.; McGregor, I. S.; Kassiou, M. ACS Chem. Neurosci. 2013, 4, 1081−1092. 
11 Kerchner, H. A.; Montgomery, J. Org. Lett. 2016, 18, 5760–5763. 
12 Greulich, T.W.; Daniliuc, C.J.; Studer, A. Org. Lett. 2015, 17, 254−257. 
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1-(Tert-butyldimethylsilyl)-1H-indole (15e) 
 
Following general procedure C and starting from commercially available indole (2.34 g, 20.0 
mmol), 15e (4.63 g, 20.0 mmol, quantitative yield) (CAS number 40899-73-8) was obtained 
as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.2 Hz, 1H, HAr), 7.44 (d, J = 7.7 Hz, 1H, HAr), 
7.10 (d, J = 3.2 Hz, 1H, HAr), 7.09-6.99 (m, 2H, HAr), 6.54 (d, J = 2.7 Hz, 1H, HAr), 0.85 (s, 
9H, C(CH3)3), 0.52 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 141.1, 131.5, 131.1, 121.5, 120.8, 119.9, 114.0, 104.9, 26.5, 
19.7, -3.8. Spectra data matched with the values reported in literature.13 
  
                                                   
13 Dhanak, D.; Reese, C. B. J. Chem. Soc., Perkin Trans. 1 1986, 2181–2186 
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2.5. General procedure D for the synthesis of indoleBX and pyrroleBX reagents 
 
1-Acetoxy-1,2-benziodoxol-3-(1H)-one (16) 
 
 
Following a reported procedure14, sodium periodate (18.1 g, 85.0 mmol, 1.05 equiv) and 2-iodobenzoic acid 
(20.0 g, 81.0 mmol, 1.00 equiv) were suspended in 30% (v:v) aq. AcOH (160 mL). The mixture was 
vigorously stirred and refluxed for 4 h and allowed to cool to room temperature, while protecting it from 
light. After 1 h, the crude product was collected by filtration. The crystals were washed with ice water (3 x 
40 mL) followed by acetone (45 mL) and dried under reduced pressure in the dark to afford 1-hydroxy-1,2-
benziodoxol-3-(1H)-one (20.8 g, 79.0 mmol, 98%) as a white solid. Following a reported procedure, 1-
hydroxy-1,2-benziodoxol-3-(1H)-one (20.8 g, 79.0 mmol, 1.00 equiv.) was suspended in acetic anhydride 
(75.0 mL, 788 mmol, 10.0 equiv.) and heated to reflux (140 °C) until complete dissolution (about 15 min). 
The resulting clears solution was slowly let to cool to room temperature and then cooled to 5 °C in the 
fridge. The white crystals were filtered, washed with pentane (3 x 30 mL) and dried under reduced pressure 
to afford 1-acetoxy-1,2-benziodoxol-3-(1H)-one (22.3 g, 73.0 mmol, 92%) as a white solid. 
 
 
 
Following a slightly modified reported procedure,15 1-acetoxy-1,2- benziodoxol-3-(1H)-one (1.20 equiv), 
the corresponding azaheterocycle (1.00 equiv) and zinc (II) trifluoromethanesulfonate (0.20 equiv) were 
dissolved in DCM [0.05 M]. The reaction was stirred overnight at room temperature, directly purified by 
flash chromatography (eluent DCM/MeOH see ratio thereafter) and triturated in ACN to afford the pure 
desired hypervalent iodine reagent. 
 
1-(3-1-Methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (5a) 
 
Following general procedure D, starting from commercially available 1-
methylindole (0.43 mL, 3.4 mmol) and 16, a purification by column chromatography 
(DCM/MeOH 19:1) afford the title compound 5a (0.79 g, 2.1 mmol, 61% yield) 
(CAS number 2130906-04-4) as an off-white solid. 
1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 7.5 Hz, 1H, HAr), 7.77 (s, 1H, CH-N), 
7.56-7.49 (m, 2H, HAr), 7.47-7.41 (m, 2H, HAr), 7.35-7.26 (m, 2H, HAr), 6.85 (d, J = 8.2 Hz, 1H, HAr), 4.02 
(s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 167.0, 138.7, 137.7, 133.6, 133.4, 132.7, 130.7, 129.5, 125.4, 124.5, 122.8, 
120.1, 116.3, 110.9, 79.2, 34.1. Spectra data matched with the values reported in literature.12 
  
                                                   
14 Parsons, A. T.; Buchwald, S. L. Angew. Chem. Int. Ed. 2011, 50, 9120–9123 
15 Caramenti, P.; Nicolai, S.; Waser, J. Chem. Eur. J. 2017, 23,14702–14706 
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1-(3-1-Pentyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (5b) 
 
Following general procedure D, starting from 15b (257 mg, 1.37 mmol) and 16, 
a purification by column chromatography (DCM/MeOH 19:1) afford the title 
compound 5b (357 mg, 0.820 mmol, 60% yield) as an off-white solid. mp 194-
196 °C. Rf 0.37 (DCM/MeOH 19:1). 
1H NMR (400 MHz, MeOD) δ 8.26 (d, J = 6.6 Hz, 1H, HAr), 8.15 (s, 1H, CH-
N), 7.70 (d, J = 8.3 Hz, 1H, HAr), 7.60 (t, J = 7.3 Hz, 1H, HAr), 7.48 (d, J = 8.0 Hz, 1H, HAr), 7.44-7.37 (m, 
2H, HAr), 7.29 (t, J = 7.5 Hz, 1H, HAr), 6.87 (d, J = 8.3 Hz, 1H, HAr), 4.42 (t, J = 7.0 Hz, 2H, NCH2), 2.03-
1.90 (m, 2H, Haliph), 1.47-1.24 (m, 4H, Haliph), 0.91 (t, J = 6.9 Hz, 3H, CH3). 
13C NMR (101 MHz, MeOD) δ 170.3, 140.2, 138.5, 135.0, 134.5, 133.2, 131.7, 130.6, 127.7, 125.1, 123.5, 
120.6, 116.8, 112.4, 77.9, 48.3, 30.8, 30.1, 23.3, 14.3. 
IR νmax 2927 (w), 1596 (s), 1555 (s), 1435 (m), 1340 (s), 1292 (m), 826 (s), 744 (s), 583 (s). 
HRMS calculated for C20H21INO2+ [M+H]+ 434.0612; found 434.0622. 
 
1-(3-1-(But-3-en-1-yl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (5c) 
 
Following general procedure D, starting from 15c (390 mg, 2.28 mmol) and 16, 
a purification by column chromatography (DCM/MeOH 32:1) afford the title 
compound 5c (501 mg, 1.16 mmol, 53% yield) as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 7.3 Hz, 1H, HAr), 7.73-7.68 (m, 1H, 
HAr), 7.57-7.51 (m, 2H, CH-N + HAr), 7.48-7.42 (m, 2H, HAr), 7.33-7.28 (m, 
2H, HAr), 6.77 (d, J = 8.3 Hz, 1H, HAr), 5.80 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H, CH=CH2), 5.11-5.04 (m, 2H, 
CH=CH2), 4.39 (t, J = 6.8 Hz, 2H, NCH2), 2.71 (q, J = 6.8 Hz, 2H, NCH2CH2). 
13C NMR (101 MHz, CDCl3) δ 166.9, 137.6, 137.5, 136.9, 133.6, 133.6, 133.4, 132.8, 130.8, 129.6, 125.3, 
124.5, 122.8, 120.3, 118.9, 116.4, 111.0, 79.7, 47.1, 34.3. Spectra data matched with the values reported 
in literature.12 
 
1-(3-5-Bromo-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (5d) 
 
Following general procedure D, starting from 15d (406 mg, 1.93 mmol) and 16, a 
purification by column chromatography (DCM/MeOH 19:1) afford the title 
compound 5d (470 mg, 1.03 mmol, 53% yield) as an off-white solid. mp 223-225 
°C. Rf 0.21 (DCM/MeOH 19:1). 
1H NMR (400 MHz, CD2Cl2) δ 8.33 (d, J = 7.4 Hz, 1H, HAr), 7.70 (s, 1H, CH-N), 
7.63 (s, 1H, HAr), 7.57 (t, J = 7.3 Hz, 1H, HAr), 7.52 (dd, J = 8.8, 1.6 Hz, 1H, HAr), 
7.44 (d, J = 8.8 Hz, 1H, HAr), 7.34 (t, J = 7.1 Hz, 1H, HAr), 6.84 (d, J = 8.3 Hz, 1H, HAr), 3.96 (s, 3H, NCH3). 
13C NMR (101 MHz, CD2Cl2) δ 166.6, 139.9, 136.9, 133.9, 133.7, 132.5, 131.5, 131.0, 127.5, 125.7, 123.0, 
116.7, 116.2, 112.8, 79.5, 34.4. 
IR νmax 3075 (m), 1601 (s), 1495 (s), 1347 (s), 740 (s), 685 (m). 
HRMS calculated for C16H1279BrINO2+ [M+H]+ 455.9091; found 455.9093. 
 
  
S12 
 
1-(3-1H-Indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (5e) 
 
Following general procedure D and remplacing Zn(OTf)2 by Sc(OTf)3, starting from 
15e (579 mg, 2.50 mmol) and 16, a purification by column chromatography 
(DCM/MeOH 5:1) afforded the title compound 5e (527 mg, 1.45 mmol, 58% yield) 
as a pale beige solid. 
1H NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H, NH), 8.26 (s, 1H, CH-N), 8.12 (d, 
J = 7.3 Hz, 1H, HAr), 7.64 (d, J = 8.2 Hz, 1H, HAr), 7.56 (t, J = 7.3 Hz, 1H, HAr), 7.49 (d, J = 7.9 Hz, 1H, 
HAr), 7.41 (t, J = 7.6 Hz, 1H, HAr), 7.31 (t, J = 7.6 Hz, 1H, HAr), 7.20 (t, J = 7.5 Hz, 1H, HAr), 6.76 (d, J = 
8.2 Hz, 1H, HAr). 
13C NMR (101 MHz, DMSO-d6) δ 165.8, 136.5 (2C), 134.6, 133.1, 131.3, 130.1, 128.6, 126.2, 123.3, 
121.6, 119.2, 116.0, 112.9, 80.3. Spectra data matched with the values reported in literature.12 
 
1-(3-1-Methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (5f)  
 
Following general procedure D, starting from 1-methylpyrrole (0.37 mL, 4.2 mmol) 
and 16, a purification by column chromatography (EtOAc/MeOH 9:1) afford the title 
compound 5f (763 mg, 2.33 mmol, 56% yield) (CAS number 2130906-17-9) as a 
off-white solid and 1-(2-1-methyl-1H-pyrrole)-1H-1λ3-benzo[b]iodo-3(2H)-one 
(525 mg, 1.64 mmol, 39% yield) (CAS number 2130906-18-0) as a pale brown solid. 
1H NMR (400 MHz, MeOD) δ 8.25 (dd, J = 7.5, 1.6 Hz, 1H, HAr), 7.64 (t, J = 7.3 
Hz, 1H, HAr), 7.55 (td, J = 7.8, 7.3, 1.7 Hz, 1H, HAr), 7.48-7.45 (m, 1H, HAr), 7.12 (d, J = 8.2 Hz, 1H, HAr), 
7.06-7.02 (m, 1H, HAr), 6.62 (dd, J = 2.8, 1.7 Hz, 1H, HAr), 3.87 (s, 3H, NCH3). 
13C NMR (101 MHz, MeOD) δ 170.3, 135.3, 133.8, 133.5, 133.0, 131.7, 128.1, 127.8, 117.4, 116.7, 82.4, 
37.1. Spectra data matched with the values reported in literature.11 
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3. Optimization of the transition metal-catalyzed C-H activation 
 
4a (9.8 mg, 80 µmol, 1.0 equiv.), 5a (30.3 mg, 80.0 µmol, 1.00 equiv.), metal catalyst (2.0 mg, 2.5 
µmol, 3 mol %) and base (see Table 1 below) were solubilized in dry MeOH [0.1 M]. The mixture was 
stirred at room temperature for 10 minutes. The suspension was diluted with DCM (5 mL) and 
quenched with a saturated aqueous solution of NaHCO3 (5 mL). The two layers were separated and the 
aqueous layer was extracted twice with DCM (5 mL). The organic layers were combined, dried over 
magnesium sulfate dehydrate, filtered and concentrated under reduced pressure. The crude residue was 
purified by column chromatography on silica gel using Pentane/EtOAc 85:15 as eluent to afford the pure 
title compound. 
 
Table 1: Optimization for the iridium-catalyzed 3-acylation with salicylaldehyde 4a and Me-indoleBX 5a 
 
Catalyst Temperature (°C) Base Isolated yield (%) 
- 80 CsOAc (1.2 equiv) NR 
[RhCp*Cl2]2 80 CsOAc (1.2 equiv) < 20 
[IrCp*Cl2]2 rt CsOAc (1.2 equiv) 91 
[IrCp*Cl2]2 rt NaOAc (1.2 equiv) 90 
[IrCp*Cl2]2 rt KOAc (1.2 equiv) 90 
[IrCp*Cl2]2 rt KOAc (1.0 equiv) 90 
[IrCp*Cl2]2 rt KOAc (0.5 equiv) 86a 
[IrCp*Cl2]2 rt - 56a 
[IrCp*Cl2]2 (1 mol%) rt KOAc (1.0 equiv) 94 
[IrCp*Cl2]2 (1 mol%) 80 KOAc (1.0 equiv) 53b 
[IrCp*Cl2]2 (1 mol%) 80 KOAc (1.0 equiv) 59c 
[IrCp*Cl2]2 80 KOAc (1.0 equiv) decompositiond,e 
[IrCp*Cl2]2 50 KOAc (1.0 equiv) decompositionf,e 
[IrCp*Cl2]2 50 KOAc (1.0 equiv) decompositiong,e 
 aby-products were observed. b3-Iodo-1-methylindole was used instead of 5a. c3-Bromo-1-methylindole was used instead of 5a. 
dBenzaldehyde was used instead of 4a. eNo conversion at rt. fo-Anisaldehyde was used instead of 4a. g2-Acetoxybenzaldehyde was used    
instead of 4a. 
 
Table 2: Optimization for the rhodium-catalyzed 3-acylation with N-(2-formylphenyl)-4-
methylbenzenesulfonamide 7a and Me-indoleBX 5a 
 
Catalyst Temperature (°C) Solvent Isolated yield (%) 
- 80 DCE NR 
[IrCp*Cl2]2 rt DCE 75 
[RhCp*Cl2]2 rt DCE 78 
[RhCp*Cl2]2 rt MeOH 82 
[RhCp*Cl2]2 40 MeOH 86 
[RhCp*Cl2]2 (1 mol%) 40 MeOH 89 
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4. Mechanism proposal 
 
Scheme S1: Plausible mechanism of the iridium-catalyzed C-H functionalization for salicylaldehyde 4a 
and Me-indoleBX 5a 
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Scheme S2: Plausible mechanism of the rhodium-catalyzed C-H functionalization for N-(2-
formylphenyl)-4-methylbenzenesulfonamide 7a and Me-indoleBX 5a 
 
 
Discussion: A very similar catalytic cycle can be proposed for both the iridium and rhodium catalyst. 
Ligand exchange with potassium acetate first gives the active catalyst, which reacts than with either 4a 
or 7a via coordination and C-H activation to form metallacycle II and two equivalents of acetic acid. 
In fact, metallacycle II bearing a rhodium center and L = pyridine or MeCN could be isolated in 
excellent yields using similar reaction conditions.16 In the second step, oxidative addition of 
hypervalent iodine reagent 5a onto metallacycle II gives high valent metal intermediate III. Finally, 
reductive elimination and ligand exchange regenerate the metal acetate complex. This mechanism is in 
accordance with what was proposed for alkynylation.16 Further work will be done to fully elucidate the 
mechanism of this transformation. 
 
 
 
 
  
                                                   
16 Wang, H.; Xie, F.; Qi, Z.; Li, X. Org. Lett. 2015, 17, 920. 
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5. Scope 
 
5.1. General procedure E1 for the synthesis of 3-salicyloylindoles 
 
 
 
[IrCp*Cl2]2 (1.2 mg, 1.5 µmol, 1 mol %), potassium acetate (14.8 mg, 0.150 mmol, 1.00 equiv), 
corresponding salicylaldehyde (0.15 mmol, 1.00 equiv) and the corresponding hypervalent iodine 
reagent (0.15 mmol, 1.00 equiv) were solubilized in dry MeOH (1.5 mL, 0.1 M). The mixture was 
stirred at room temperature for 10 minutes. The suspension was diluted with DCM (5 mL) and 
quenched with a saturated aqueous solution of NaHCO3 (5 mL). The two layers were separated and the 
aqueous layer was extracted twice with DCM (5 mL). The organic layers were combined, dried over 
magnesium sulfate dehydrate, filtered and concentrated under reduced pressure. The crude residue was 
purified by column chromatography on silica gel using the indicated solvents to afford the pure title 
compound. 
 
5.2 General procedure E2 for the synthesis of 3-(2-sulfonamino)benzoylindoles 
 
 
 
[RhCp*Cl2]2 (0.93 mg, 1.5 µmol, 1 mol %), potassium acetate (14.8 mg, 0.150 mmol, 1.00 equiv), 
corresponding salicylaldehyde (0.15 mmol, 1.00 equiv) and corresponding hypervalent iodine reagent 
(0.15 mmol, 1.00 equiv) were solubilized in dry MeOH (1.5 mL, 0.1 M). The mixture was stirred at 40 
°C for 4 hours. The suspension was diluted with DCM (5 mL) and quenched with a saturated aqueous 
solution of NaHCO3 (5 mL). The two layers were separated and the aqueous layer was extracted twice 
with DCM (5 mL). The organic layers were combined, dried over magnesium sulfate dehydrate, filtered 
and concentrated under reduced pressure. The crude residue was purified by column chromatography 
on silica gel using the indicated solvents to afford the pure title compound. 
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(2-Hydroxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6a) 
 
Following General Procedure E1, starting from commercially available 
salicylaldehyde and Me-indoleBX 5a, a purification by column chromatography on 
silica gel (Pentane/EtOAc 85:15) afford the title compound 6a (35.4 mg, 0.140 
mmol, 94% yield) or (281 mg, 1.12 mmol, 93% yield) as a yellow solid. mp 128-
130 °C. Rf 0.46 (Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.06 (bs, 1H, OH), 8.33-8.28 (m, 1H, HAr), 7.84 (dd, J = 7.9, 1.6 Hz, 1H, 
HAr), 7.62 (s, 1H, CH-N), 7.46 (ddd, J = 8.6, 7.4, 1.6 Hz, 1H, HAr), 7.40-7.32 (m, 3H, HAr), 7.06 (d, J = 8.3 
Hz, 1H, HAr), 6.92 (t, J = 8.0 Hz, 1H, HAr), 3.86 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 193.5, 162.0, 137.4, 137.0, 134.7, 131.5, 127.3, 123.9, 122.8, 122.4, 121.4, 
118.7, 118.2, 114.7, 109.9, 33.8. 
IR νmax 1586 (s), 1521 (s), 1463 (s), 1370 (s), 1330 (m), 1276 (m), 1236 (s), 1200 (s), 1154 (s), 1128 (s), 
1099 (s), 887 (s), 743 (s), 663 (s). 
HRMS calculated for C16H13NO2+ [M+H]+ 252.1019; found 252.1022. 
 
(2-Hydroxy-5-methylphenyl)(1-methyl-1H-indol-3-yl)methanone (6b) 
 
Following General Procedure E1, starting from commercially available 2-hydroxy-
5-methylbenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 85:15) afford the title compound 6b 
(35.4 mg, 0.134 mmol, 89% yield) as a yellow solid. mp 170-172 °C. Rf 0.40 
(Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 11.82 (bs, 1H, OH), 8.30-8.26 (m, 1H, HAr), 7.63 (d, J = 1.4 Hz, 1H, HAr), 
7.61 (s, 1H, CH-N), 7.39-7.31 (m, 3H, HAr), 7.27 (dd, J = 8.7, 2.0 Hz, 1H, HAr), 6.96 (d, J = 8.4 Hz, 1H, 
HAr), 3.87 (s, 3H, NCH3), 2.33 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 193.6, 159.8, 137.4, 136.8, 135.6, 131.4, 127.7, 127.4, 123.8, 122.7, 122.5, 
121.2, 117.9, 114.8, 109.9, 33.7, 20.7. 
IR νmax 2913 (w), 1564 (s), 1521 (s), 1469 (s), 1343 (s), 1219 (s), 1109 (s), 823 (s), 748 (s). 
HRMS calculated for C17H16NO2+ [M+H]+ 266.1176; found 266.1177. 
 
(2-Hydroxy-5-methoxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6c) 
 
Following General Procedure E1, starting from commercially available 2-hydroxy-
5-methoxybenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 7:3) afford the title compound 6c 
(38.0 mg, 0.135 mmol, 90% yield) as a yellow solid. mp 147-149 °C. Rf 0.24 
(Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 11.45 (bs, 1H, OH), 8.31-8.27 (m, 1H, HAr), 7.68 (s, 
1H, CH-N), 7.41-7.33 (m, 4H, HAr), 7.10 (dd, J = 9.0, 3.1 Hz, 1H, HAr), 7.01 (d, J = 9.0 Hz, 1H, HAr), 3.88 
(s, 3H, OCH3), 3.79 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 193.1, 155.9, 151.7, 137.5, 136.8, 127.3, 123.9, 122.9, 122.5, 121.4, 121.2, 
118.8, 115.9, 114.9, 110.0, 56.2, 33.8. 
IR νmax 3102 (w), 2927 (m), 2852 (w), 1562 (s), 1520 (s), 1484 (s), 1460 (s), 1221 (s), 1101 (s), 1035 (s), 
828 (s), 742 (s), 670 (s). 
HRMS calculated for C17H16NO3+ [M+H]+ 282.1125; found 282.1128. 
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(5-Fluro-2-hydroxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6d) 
 
Following General Procedure E1, starting from commercially available 5-fluoro-2-
hydroxybenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 85:15) afford the title compound 6d 
(36.3 mg, 0.135 mmol, 90% yield) as a yellow solid. mp 160-162 °C. Rf 0.51 
(Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 11.71 (s, 1H, OH), 8.32-8.29 (m, 1H, HAr), 7.65 (s, 1H, CH-N), 7.54 (dd, J 
= 9.0, 3.1 Hz, 1H, HAr), 7.42-7.34 (m, 3H, HAr), 7.23-7.17 (m, 1H, HAr), 7.01 (dd, J = 9.1, 4.6 Hz, 1H, 
HAr), 3.89 (s, 3H, NCH3). 
19F NMR (376 MHz, CDCl3) δ -124.7. 
13C NMR (101 MHz, CDCl3) δ 192.2 (d, J = 2.2 Hz), 158.0 (d, J = 1.5 Hz), 155.0 (d, J = 237.5 Hz), 137.5, 
136.9, 127.2, 124.1, 123.1, 122.5, 121.7 (d, J = 23.4 Hz), 121.1 (d, J = 6.1 Hz), 119.3 (d, J = 7.3 Hz), 116.7 
(d, J = 23.7 Hz), 114.4, 110.0, 33.9. 
IR νmax 2927 (w), 1571 (m), 1525 (s), 1464 (s), 1423 (m), 1341 (s), 1222 (s), 1125 (s), 1099 (s), 829 (s), 791 
(s), 750 (s), 676 (s). 
HRMS calculated for C16H13FNO2+ [M+H]+ 270.0925; found 270.0930. 
 
(5-Chloro-2-hydroxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6e) 
 
Following General Procedure E1, starting from commercially available 5-chloro-2-
hydroxybenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 85:15) afford the title compound 6e 
(39.3 mg, 0.138 mmol, 92% yield) as a yellow solid. mp 187-189 °C. Rf 0.58 
(Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 11.90 (s, 1H, OH), 8.29 (dd, J = 5.9, 2.4 Hz, 1H, HAr), 7.82 (d, J = 2.5 Hz, 
1H, HAr), 7.66 (s, 1H, CH-N), 7.43-7.34 (m, 4H, HAr), 7.01 (d, J = 8.8 Hz, 1H, HAr), 3.92 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.1, 160.5, 137.6, 137.0, 134.4, 130.5, 127.3, 124.2, 123.4, 123.2, 122.5, 
122.2, 119.8, 114.5, 110.1, 33.9. 
IR νmax 1563 (m), 1521 (s), 1470 (s), 1335 (s), 1276 (s), 1217 (s), 1128 (m), 812 (s), 748 (s), 723 (s). 
HRMS calculated for C16H13ClNO2+ [M+H]+ 286.0629; found 286.0636. 
 
(5-Bromo-2-hydroxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6f) 
 
Following General Procedure E1, starting from commercially available 5-bromo-2-
hydroxybenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 85:15) afford the title compound 6f 
(44.4 mg, 0.135 mmol, 90% yield) as a yellow solid. mp 171-173 °C. Rf 0.58 
(Pentane/EtOAc 4:1) 
 
1H NMR (400 MHz, CDCl3) δ 11.93 (s, 1H, OH), 8.32-8.25 (m, 1H, HAr), 7.96 (d, J = 2.5 Hz, 1H, HAr), 
7.65 (s, 1H, CH-N), 7.54 (dd, J = 8.8, 2.5 Hz, 1H, HAr), 7.43-7.34 (m, 3H, HAr), 6.96 (d, J = 8.8 Hz, 1H, 
HAr), 3.91 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.0, 160.9, 137.6, 137.2, 137.0, 133.5, 127.2, 124.2, 123.2, 122.8, 122.5, 
120.2, 114.4, 110.4, 110.1, 34.0. 
IR νmax 2913 (w), 1565 (m), 1523 (s), 1463 (s), 1337 (s), 1274 (m), 1215 (s), 812 (m), 746 (s). 
HRMS calculated for C16H1379BrNO2+ [M+H]+ 330.0124; found 330.0129. 
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(2-Hydroxy-5-iodophenyl)(1-methyl-1H-indol-3-yl)methanone (6g) 
 
Following General Procedure E1, starting from commercially available 5-iodo-2-
hydroxybenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 85:15) afford the title compound 6g 
(50.1 mg, 0.133 mmol, 89% yield) as a yellow solid. mp 181-183 °C. Rf 0.61 
(Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 11.94 (s, 1H, OH), 8.29-8.25 (m, 1H, HAr), 8.13 (d, J = 2.2 Hz, 1H, HAr), 
7.70 (dd, J = 8.7, 2.2 Hz, 1H, HAr), 7.63 (s, 1H, CH-N), 7.43-7.34 (m, 3H, HAr), 6.85 (d, J = 8.7 Hz, 1H, 
HAr), 3.92 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 191.9, 161.6, 142.9, 139.5, 137.6, 137.0, 127.2, 124.2, 123.7, 123.2, 122.5, 
120.7, 114.5, 110.1, 79.7, 34.0. 
IR νmax 1570 (s), 1554 (s), 1520 (s), 1461 (s), 1337 (s), 1272 (s), 1213 (s), 1108 (s), 888 (s), 808 (s), 755 (s), 
736 (s). 
HRMS calculated for C16H13INO2+ [M+H]+ 377.9986; found 377.9984. 
 
4-Hydroxy-3-(1-methyl-1H-indole-3-carbonyl)benzaldehyde (6h) 
 
Following General Procedure E1, starting from commercially available 4-
hydroxyisophthalaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 3:2) afford the title compound 6h 
(34.3 mg, 0.123 mmol, 82% yield) as a yellow solid. mp 203-205 °C. Rf 0.50 
(Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.84 (s, 1H, OH), 9.90 (s, 1H, CHO), 8.43 (d, J = 2.0 Hz, 1H, HAr), 8.32-
8.27 (m, 1H, HAr), 7.98 (dd, J = 8.6, 2.1 Hz, 1H, HAr), 7.71 (s, 1H, CH-N), 7.44-7.35 (m, 3H, HAr), 7.17 (d, 
J = 8.6 Hz, 1H, HAr), 3.93 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.6, 190.3, 167.5, 137.6, 137.2, 135.9, 133.6, 128.1, 127.3, 124.4, 123.3, 
122.5, 121.3, 119.2, 114.4, 110.1, 34.0. 
IR νmax 3115 (w), 2921 (m), 1693 (s), 1609 (s), 1562 (s), 1525 (s), 1469 (s), 1354 (s), 1229 (s), 1102 (s), 
834 (s), 741 (s), 725 (s). 
HRMS calculated for C17H14NO3+ [M+H]+ 280.0968; found 280.0966. 
  
(2-Hydroxy-5-nitrophenyl)(1-methyl-1H-indol-3-yl)methanone (6i) 
 
Following General Procedure E1, starting from commercially available 2-hydroxy-
5-nitrobenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/DCM 1:1) afford the title compound 6i (32.9 
mg, 0.111 mmol, 74% yield) as a yellow solid. mp 227-229 °C. Rf 0.44 
(Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.97 (s, 1H, OH), 8.86 (d, J = 2.7 Hz, 1H, HAr), 8.35 (dd, J = 9.2, 2.7 Hz, 
1H, HAr), 8.33-8.29 (m, 1H, HAr), 7.75 (s, 1H, CH-N), 7.47-7.37 (m, 3H, HAr), 7.14 (d, J = 9.2 Hz, 1H, HAr), 
3.96 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 191.6, 167.6, 139.7, 137.8, 137.4, 129.7, 127.6, 127.3, 124.7, 123.7, 122.7, 
120.4, 119.3, 114.2, 110.4, 34.3. 
IR νmax 1581 (m), 1522 (s), 1458 (m), 1341 (s), 1286 (s), 1224 (s), 1095 (m), 832 (s), 735 (s), 722 (s). 
HRMS calculated for C16H13N2O4+ [M+H]+ 297.0870; found 297.0874. 
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(2-Hydroxy-3-methoxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6j) 
 
Following General Procedure E1, starting from commercially available 2-
hydroxy-3-methoxybenzaldehyde and Me-indoleBX 5a, a purification by 
column chromatography on silica gel (Pentane/EtOAc 7:3) afford the title 
compound 6j (39.6 mg, 0.141 mmol, 94% yield) as a yellow solid. mp 134-
136 °C. Rf 0.56 (Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.22 (bs, 1H, OH), 8.32-8.28 (m, 1H, HAr), 7.61 (s, 1H, CH-N), 7.42 (dd, 
J = 8.0, 1.4 Hz, 1H, HAr), 7.36-7.30 (m, 3H, HAr), 7.05 (dd, J = 8.0, 1.3 Hz, 1H, HAr), 6.86 (t, J = 8.0 Hz, 
1H, HAr), 3.92 (s, 3H, OCH3), 3.84 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 193.5, 152.0, 148.9, 137.4, 137.3, 127.3, 123.9, 122.9, 122.8, 122.5, 121.6, 
118.1, 115.6, 114.8, 109.9, 56.3, 33.7. 
IR νmax 2933 (w), 1563 (s), 1524 (s), 1461 (s), 1350 (s), 1239 (s), 1088 (m), 931 (m), 743 (s). 
HRMS calculated for C17H16NO3+ [M+H]+ 282.1125; found 282.1132. 
 
(2-Hydroxy-4-methoxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6k) 
 
Following General Procedure E1, starting from commercially available 2-
hydroxy-4-methoxybenzaldehyde and Me-indoleBX 5a, a purification by 
column chromatography on silica gel (Pentane/EtOAc 4:1) afford the title 
compound 6k (39.2 mg, 0.140 mmol, 93% yield) as a yellow solid. mp 133-
135 °C. Rf 0.40 (Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.88 (s, 1H, OH), 8.24-8.20 (m, 1H, HAr), 7.79 (d, J = 8.8 Hz, 1H, HAr), 
7.58 (s, 1H, CH-N), 7.38-7.29 (m, 3H, HAr), 6.52 (d, J = 2.5 Hz, 1H, HAr), 6.45 (dd, J = 8.9, 2.5 Hz, 1H, 
HAr), 3.85 (s, 6H, OCH3+ NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.7, 165.2, 165.1, 137.3, 135.8, 133.3, 127.3, 123.6, 122.5, 122.3, 114.9, 
114.7, 109.9, 106.8, 101.3, 55.6, 33.6. 
IR νmax 2920 (w), 2839 (w), 1618 (s), 1560 (s), 1505 (s), 1459 (s), 1369 (s), 1340 (s), 1299 (s), 1267 (s), 
1241 (s), 1221 (s), 1145 (s), 1107 (s), 852 (s), 751 (s). 
HRMS calculated for C17H16NO3+ [M+H]+ 282.1125; found 282.1127. 
 
(2-Hydroxy-6-methoxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6l) 
 
Following General Procedure E1 (30 minutes), starting from 2-hydroxy-6-
methoxybenzaldehyde 13  and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 7:3) afford the title compound 6l 
(36.1 mg, 0.128 mmol, 86% yield) as a off-white solid. mp 250-252 °C. Rf 0.54 
(Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, DMSO-d6) δ 9.49 (s, 1H, OH), 8.09 (d, J = 7.6 Hz, 1H, HAr), 7.60 (s, 1H, CH-N), 
7.52 (d, J = 8.0 Hz, 1H, HAr), 7.26 (dtd, J = 21.1, 7.2, 1.2 Hz, 2H, HAr), 7.18 (t, J = 8.3 Hz, 1H, HAr), 6.55 
(dd, J = 8.2, 4.3 Hz, 2H, HAr), 3.80 (s, 3H, NCH3), 3.63 (s, 3H, OCH3). 
13C NMR (101 MHz, DMSO-d6) δ 188.0, 157.2, 154.9, 138.9, 137.5, 129.6, 125.7, 122.8, 122.1, 121.2, 
188.6, 116.9, 110.7, 108.7, 102.1, 55.4, 33.0. 
IR νmax 3150 (br), 1596 (s), 1573 (s), 1527 (s), 1459 (s), 1371 (s), 1227 (s), 1078 (s), 876 (s), 757 (s), 741 
(s), 712 (s). 
HRMS calculated for C17H16NO3+ [M+H]+ 282.1125; found 282.1124. 
  
S21 
 
(2-Hydroxy-3-methylphenyl)(1-methyl-1H-indol-3-yl)methanone (6m) 
 
Following General Procedure E1, starting from commercially available 2-
hydroxy-3-methylbenzaldehyde and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 85:15) afforded the title 
compound 6m (34.9 mg, 0.132 mmol, 88% yield) as a yellow solid. mp 110-112 
°C. Rf 0.45 (Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.31 (bs, 1H, OH), 8.31-8.28 (m, 1H, HAr), 7.70 (dd, J = 7.9, 1.2 Hz, 1H, 
HAr), 7.61 (s, 1H, CH-N), 7.39-7.32 (m, 4H, HAr), 6.83 (t, J = 7.6 Hz, 1H, HAr), 3.86 (s, 3H, NCH3), 2.34 (s, 
3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 194.0, 160.4, 137.4, 136.9, 135.6, 129.2, 127.4, 127.1, 123.8, 122.7, 122.5, 
120.7, 118.0, 114.9, 109.9, 33.7, 15.9. 
IR νmax 2906 (w), 1599 (m), 1562 (m), 1517 (s), 1471 (m), 1425 (m), 1339 (s), 1238 (s), 1078 (s), 741 (s). 
HRMS calculated for C17H16NO2+ [M+H]+ 266.1176; found 266.1179. 
 
(3,5-Di-tert-butyl-2-hydroxyphenyl)(1-methyl-1H-indol-3-yl)methanone (6n) 
 
Following General Procedure E1 (60 minutes), starting from commercially 
available 3,5-di-tert-butyl-2-hydroxybenzaldehyde and Me-indoleBX 5a, a 
purification by column chromatography on silica gel (Pentane/Et2O 9:1) 
afforded the title compound 6n (30.8 mg, 0.085 mmol, 85% yield) as a yellow 
solid. mp 210-212 °C. Rf 0.78 (Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.49 (s, 1H, OH), 8.24 (dd, J = 6.8, 1.4 Hz, 
1H, HAr), 7.73 (d, J = 2.5 Hz, 1H, HAr), 7.61 (s, 1H, CH-N), 7.56 (d, J = 2.4 Hz, 1H, HAr), 7.42-7.31 (m, 3H, 
HAr), 3.89 (s, 3H, NCH3), 1.50 (s, 9H, C(CH3)3), 1.32 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, CDCl3) δ 194.8, 159.0, 139.5, 137.4, 137.3, 136.5, 129.3, 127.3, 126.2, 123.6, 122.5 
(2C), 120.5, 115.5, 109.8, 35.2, 34.3, 33.6, 31.5, 29.5. 
IR νmax 2947 (m), 2866 (m), 1567 (s), 1518 (s), 1459 (s), 1429 (s), 1361 (s), 1217 (s), 1125 (s), 1078 (s), 
799 (s), 750 (s), 731 (s). 
HRMS calculated for C24H30NO2+ [M+H]+ 364.2271; found 364.2280. 
 
 (2-Hydroxynaphthalen-1-yl)(1-methyl-1H-indol-3-yl)methanone (6o) 
 
Following General Procedure E1, starting from commercially available 2-hydroxy-
1-naphthaldehyde and Me-indoleBX 5a, a purification by column chromatography 
on silica gel (Pentane/EtOAc 7:3) afforded the title compound 6o (44.1 mg, 0.136 
mmol, 91% yield) as a white solid. mp 261-263 °C. Rf 0.65 (Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H, OH), 8.21 (bs, 1H, HAr), 7.87 (t, J 
= 8.1 Hz, 2H, HAr), 7.59 (s, 1H, CH-N), 7.54 (d, J = 7.4 Hz, 1H, HAr), 7.45 (d, J = 8.2 Hz, 1H, HAr), 7.36-
7.26 (m, 5H, HAr), 3.76 (s, 3H, NCH3). 
13C NMR (101 MHz, DMSO-d6) δ 190.4, 151.3, 139.6, 137.6, 131.9, 129.7, 128.0, 127.5, 126.6, 125.8, 
123.6, 123.0, 122.8, 122.3, 122.0, 121.3, 118.5, 117.0, 110.8, 33.0. 
IR νmax 3109 (br), 1594 (s), 1524 (s), 1459 (m), 1368 (m), 1347 (m), 1242 (m), 1212 (s), 1090 (m), 819 (m), 
754 (s). 
HRMS calculated for C20H15NNaO2+ [M+Na]+ 324.0995; found 324.0991. 
  
S22 
 
(8R,9S,13S,14S)-3-Hydroxy-13-methyl-2-(1-methyl-1H-indole-3-carbonyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one (6p) 
 
Following General Procedure E1, starting from 2-formyl estrone 13 
and Me-indoleBX 5a, a purification by column chromatography on 
silica gel (Pentane/EtOAc 3:2) afforded the title compound 6p (63.0 
mg, 0.147 mmol, 98% yield) as a yellow solid. mp 135-137 °C. Rf 
0.62 (Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 11.85 (bs, 1H, OH), 8.23 (d, J = 7.2 Hz, 1H, HAr), 7.76 (s, 1H, HAr), 7.61 
(s, 1H, CH-N), 7.40-7.30 (m, 3H, HAr), 6.78 (s, 1H, HAr), 3.90 (s, 3H, NCH3), 3.00-2.92 (m, 2H, Haliph), 
2.52 (dd, J = 18.6, 8.7 Hz, 1H, Haliph), 2.32-2.22 (m, 2H, Haliph), 2.20-2.00 (m, 3H, Haliph), 1.96-1.89 (m, 
1H, Haliph), 1.70-1.40 (m, 6H, Haliph), 0.93 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 220.8, 193.6, 159.8, 144.8, 137.5, 136.2, 130.4, 128.6, 127.3, 123.9, 
122.7, 122.5, 119.5, 117.6, 115.1, 109.9, 50.5, 48.1, 43.9, 38.4, 36.0, 33.9, 31.6, 29.9, 26.4, 26.1, 21.7, 
14.0. 
IR νmax 2927 (m), 2852 (w), 1736 (s), 1566 (m), 1521 (s), 1463 (s), 1363 (s), 1221 (s), 847 (s), 737 (s). 
HRMS calculated for C28H29NNaO3+ [M+Na]+ 450.2040; found 450.2041. 
 
(4-Hydroxy-9H-carbazol-3-yl)(1-methyl-1H-indol-3-yl)methanone (6q) 
 
Following General Procedure E1, starting from 4-hydroxy-9H-carbazole-
3-carbaldehyde 4q and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 1:1) afford the title 
compound 6q (45.9 mg, 0.135 mmol, 90% yield) as a ochre solid. mp 238-
240 °C. Rf 0.36 (Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 13.84 (s, 1H, OH), 8.46 (d, J = 7.7 Hz, 1H, HAr), 8.28-8.23 (m, 2H, NH + 
HAr), 7.93 (d, J = 8.6 Hz, 1H, HAr), 7.65 (s, 1H, CH-N), 7.46-7.29 (m, 6H, HAr), 6.92 (d, J = 8.6 Hz, 1H, 
HAr), 3.89 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 193.8, 161.4, 144.3, 138.8, 137.4, 135.7, 130.2, 127.5, 125.5, 123.6, 123.5, 
123.4, 122.5, 122.4, 121.0, 115.3, 113.2, 112.1, 110.4, 109.9, 101.9, 33.7. 
IR νmax 3672 (w), 2982 (s), 2902 (s), 1590 (m), 1524 (m), 1459 (m), 1393 (s), 1382 (s), 1368 (s), 1263 (s), 
1240 (s), 1230 (s), 1075 (s), 1045 (s), 740 (s), 720 (s). 
HRMS calculated for C22H17N2O2+ [M+H]+ 341.1285; found 341.1288. 
 
(2-Hydroxyphenyl)(1-pentyl-1H-indol-3-yl)methanone (6r) 
 
Following General Procedure E1, starting from commercially available 
salicylaldehyde and Pe-indoleBX 5b, a purification by column 
chromatography on silica gel (Pentane/EtOAc 19:1) afford the title compound 
6r (42.5 mg, 0.138 mmol, 92% yield) as a yellow solid. mp 76-78 °C. Rf 0.85 
(Pentane/EtOAc 4:1). 
1H NMR (400 MHz, CDCl3) δ 12.07 (bs, 1H, OH), 8.34-8.29 (m, 1H, HAr), 7.86 (dd, J = 7.9, 1.6 Hz, 1H, 
HAr), 7.68 (s, 1H, CH-N), 7.48 (ddd, J = 8.8, 7.3, 1.7 Hz, 1H, HAr), 7.44-7.40 (m, 1H, HAr), 7.38-7.32 (m, 
2H, HAr), 7.07 (d, J = 8.3 Hz, 1H, HAr), 6.94 (t, J = 7.6 Hz, 1H, HAr), 4.19 (t, J = 7.2 Hz, 2H, NCH2), 1.90 
(p, J = 7.3 Hz, 2H, Haliph), 1.43-1.30 (m, 4H, Haliph), 0.91 (t, J = 6.9 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 193.6, 162.0, 136.8, 136.1, 134.6, 131.5, 127.5, 123.8, 122.8, 122.6, 121.5, 
118.7, 118.2, 114.7, 110.2, 47.4, 29.7, 29.1, 22.3, 14.0. 
IR νmax 2927 (m), 2859 (m), 1564 (m), 1517 (s), 1482 (s), 1463 (s), 1388 (s), 1347 (m), 1216 (m), 1194 (s), 
1131 (s), 887 (m), 765 (s), 736 (s), 671 (s). 
HRMS calculated for C20H22NO2+ [M+H]+ 308.1645; found 308.1648. 
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(2-Hydroxy-4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone (6s) 
 
Following General Procedure E1, starting from commercially available 
2-hydroxy-4-methoxybenzaldehyde and Pe-indoleBX 5b, a purification 
by column chromatography on silica gel (Pentane/EtOAc 9:1) afforded 
the title compound 6s (45.0 mg, 0.133 mmol, 89% yield) as a yellow 
solid. mp 87-89 °C. Rf 0.75 (Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.85 (bs, 1H, OH), 8.25-8.21 (m, 1H, HAr), 7.80 (d, J = 8.8 Hz, 1H, HAr), 
7.65 (s, 1H, CH-N), 7.43-7.38 (m, 1H, HAr), 7.35-7.28 (m, 2H, HAr), 6.54 (d, J = 2.5 Hz, 1H, HAr), 6.47 
(dd, J = 8.8, 2.5 Hz, 1H, HAr), 4.19 (t, J = 7.2 Hz, 2H, NCH2), 3.86 (s, 3H, OCH3), 1.90 (p, J = 7.4 Hz, 2H, 
Haliph), 1.42-1.30 (m, 4H, Haliph), 0.91 (t, J = 6.9 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 192.8, 165.2, 165.1, 136.7, 134.9, 133.3, 127.5, 123.5, 122.4, 122.4, 115.0, 
114.7, 110.1, 106.9, 101.3, 55.6, 47.3, 29.7, 29.1, 22.4, 14.0. 
IR νmax 2954 (m), 2927 (m), 2859 (m), 1625 (m), 1563 (s), 1517 (s), 1498 (s), 1461 (s), 1387 (s), 1267 (s), 
1233 (s), 1165 (s), 1112 (s), 850 (s), 779 (s), 739 (s). 
HRMS calculated for C21H24NO3+ [M+H]+ 338.1751; found 338.1753. 
 
(2-Hydroxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (6t) 
 
Following General Procedure E1, starting from commercially available 2-
hydroxy-1-naphthaldehyde and Pe-indoleBX 5b, a purification by column 
chromatography on silica gel (Pentane/EtOAc 6:1) afforded the title 
compound 6t (47.2 mg, 0.132 mmol, 88% yield) as an off-white solid. mp 
154-156 °C. Rf 0.48 (Pentane/EtOAc 4:1). 
 
1H NMR (400 MHz, CDCl3) δ 9.87 (bs, 1H, OH), 8.37-8.33 (m, 1H, HAr), 7.95 (d, J = 8.5 Hz, 1H, HAr), 
7.89 (d, J = 8.9 Hz, 1H, HAr), 7.78 (d, J = 8.1 Hz, 1H, HAr), 7.41-7.20 (m, 7H, CH-N + HAr), 4.02 (t, J = 7.0 
Hz, 2H, NCH2), 1.76 (p, J = 7.1 Hz, 2H), 1.33-1.17 (m, 4H), 0.86 (t, J = 7.1 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 192.3, 157.4, 138.5, 137.0, 133.7, 132.7, 128.9, 128.4, 127.0, 126.3 (2C), 
123.8, 123.7, 123.3, 122.9, 119.2, 117.9, 117.5, 110.4, 47.4, 29.7, 29.0, 22.4, 14.1. 
IR νmax 3265 (br), 2947 (m), 1588 (s), 1513 (s), 1462 (m), 1384 (s), 1177 (s), 1131 (s), 751 (s). 
HRMS calculated for C24H24NO2+ [M+H]+ 358.1802; found 358.1808. 
 
(1-(But-3-en-1-yl)-1H-indol-3-yl)(2-hydroxy-4-methoxyphenyl)methanone (6u) 
 
Following General Procedure E1, but performing the reaction at 70 °C, 
starting from commercially available 2-hydroxy-4-methoxybenzaldehyde 
and butenyl-indoleBX 5c, a purification by column chromatography on silica 
gel (Pentane/EtOAc 9:1) afford the title compound 6u (43.4 mg, 0.135 mmol, 
90% yield) as a yellow oil. Rf 0.56 (Pentane/EtOAc 4:1). 
1H NMR (400 MHz, CDCl3) δ 12.83 (bs, 1H, OH), 8.24-8.22 (m, 1H, HAr), 7.79 (d, J = 8.8 Hz, 1H, HAr), 
7.64 (s, 1H, CH-N), 7.43-7.40 (m, 1H, HAr), 7.36-7.29 (m, 2H, HAr), 6.54 (d, J = 2.5 Hz, 1H, HAr), 6.47 
(dd, J = 8.9, 2.5 Hz, 1H, HAr), 5.80 (ddt, J = 17.1, 10.3, 6.9 Hz, 1H, HAr), 5.13-5.06 (m, 2H, HAr), 4.26 (t, J 
= 7.0 Hz, 2H, NCH2), 3.87 (s, 3H, OCH3), 2.65 (q, J = 7.0 Hz, 2H, NCH2CH2). 
13C NMR (101 MHz, CDCl3) δ 192.8, 165.2, 165.2, 136.5, 135.0, 133.8, 133.3, 127.5, 123.6, 122.5, 118.5, 
115.0, 114.8, 110.0, 106.9, 101.3, 55.6, 46.7, 34.2. 
IR νmax 2927 (w), 2852 (w), 1619 (s), 1582 (s), 1517 (s), 1461 (s), 1388 (s), 1365 (s), 1259 (s), 1231 (s), 
1202 (s), 1160 (s), 1107 (s), 868 (s), 837 (s), 741 (s). 
HRMS calculated for C20H20NO3+ [M+H]+ 322.1438; found 322.1435. 
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(5-Bromo-1-methyl-1H-indol-3-yl)(2-hydroxy-4-methoxyphenyl)methanone (6v) 
 
Following General Procedure E1, starting from commercially available 2-
hydroxy-4-methoxybenzaldehyde and Me-bromoindoleBX 5d, a purification 
by column chromatography on silica gel (Pentane/EtOAc 4:1) afforded the 
title compound 6v (46.5 mg, 0.129 mmol, 86% yield) as a yellow solid. mp 
186-188 °C. Rf 0.53 (Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 12.75 (s, 1H, OH), 8.37 (d, J = 1.8 Hz, 1H, HAr), 7.73 (d, J = 8.8 Hz, 1H, 
HAr), 7.55 (s, 1H, CH-N), 7.39 (dd, J = 8.7, 1.9 Hz, 1H, HAr), 7.20 (d, J = 8.7 Hz, 1H, HAr), 6.50 (d, J = 2.5 
Hz, 1H, HAr), 6.45 (dd, J = 8.8, 2.5 Hz, 1H, HAr), 3.86 (s, 3H, OCH3), 3.85 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.2, 165.4, 165.4, 136.5, 136.1, 133.1, 129.0, 126.8, 125.1, 116.3, 114.7, 
114.3, 111.4, 107.2, 101.5, 55.8, 34.0. 
IR νmax 2920 (m), 2852 (m), 1628 (m), 1574 (s), 1504 (s), 1460 (s), 1338 (s), 1291 (s), 1233 (s), 1137 (s), 
1113 (s), 1020 (s), 796 (s), 764 (s). 
HRMS calculated for C17H1579BrNO3+ [M+H]+ 360.0230; found 360.0232. 
 
(2-Hydroxy-4-methoxyphenyl)(1H-indol-3-yl)methanone (6w) 
 
Following General Procedure E1, but performing the reaction at 70 °C, 
starting from commercially available 2-hydroxy-4-methoxybenzaldehyde and 
NH-indoleBX 5e, a purification by column chromatography on silica gel 
(Pentane/EtOAc 4:1) afforded the title compound 6w (34.1 mg, 0.128 mmol, 
85% yield) as a yellow solid. mp 175-177 °C. Rf 0.63 (Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 12.85 (bs, 1H, OH), 8.73 (s, 1H, NH), 8.24-8.15 (m, 1H, HAr), 7.81 (d, J = 
8.9 Hz, 1H, HAr), 7.72 (d, J = 2.9 Hz, 1H, HAr), 7.48-7.40 (m, 1H, HAr), 7.34-7.28 (m, 2H, HAr), 6.54 (d, J 
= 2.4 Hz, 1H, HAr), 6.46 (dd, J = 8.9, 2.5 Hz, 1H, HAr), 3.87 (s, 3H, OCH3). 
13C NMR (101 MHz, CDCl3) δ 193.4, 165.4 (2C), 136.2, 133.5, 131.3, 126.5, 124.1, 122.6, 122.2, 116.5, 
114.9, 111.6, 107.1, 101.4, 55.7. 
IR νmax 3244 (br), 1615 (m), 1567 (s), 1500 (s), 1425 (s), 1358 (s), 1195 (s), 1109 (s), 871 (s), 835 (s), 741 
(s). 
HRMS calculated for C16H14NO3+ [M+H]+ 268.0968; found 268.0980. 
 
(2-Hydroxy-4-methoxyphenyl)(1-methyl-1H-pyrrol-3-yl)methanone (6x) 
 
Following General Procedure E1, starting from commercially available 2-
hydroxy-4-methoxybenzaldehyde and Me-pyrroleBX 5f, a purification by column 
chromatography on silica gel (Pentane/EtOAc 4:1) afforded the title compound 6x 
(30.3 mg, 0.131 mmol, 87% yield) as a pale yellow oil. Rf 0.31 (Pentane/EtOAc 
4:1). 
1H NMR (400 MHz, CDCl3) δ 12.99 (s, 1H, OH), 7.88 (d, J = 8.9 Hz, 1H, HAr), 7.23 (s, 1H, CH-N), 6.64 
(t, J = 1.9 Hz, 2H, HAr), 6.48 (d, J = 2.5 Hz, 1H, HAr), 6.44 (dd, J = 8.9, 2.5 Hz, 1H, HAr), 3.84 (s, 3H, 
OCH3), 3.72 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.7, 165.6, 165.2, 133.6, 127.7, 123.8, 123.2, 114.3, 111.2, 106.9, 101.2, 
55.6, 36.8. 
IR νmax 2927 (w), 1608 (s), 1584 (s), 1524 (s), 1500 (s), 1443 (s), 1353 (s), 1236 (s), 1212 (s), 1149 (s), 
1110 (s), 961 (s), 856 (s), 829 (s), 766 (s). 
HRMS calculated for C13H14NO3+ [M+H]+ 232.0968; found 232.0971. 
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4-Methyl-N-(2-(1-methyl-1H-indole-3-carbonyl)phenyl)benzenesulfonamide (8a) 
 
Following General Procedure E2, starting from N-(2-formylphenyl)4-
methylbenzenesulfonamide 7a and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 7:3) afforded the title compound 8a 
(53.3 mg, 0.132 mmol, 88% yield) as a white solid. mp 75-77 °C. Rf 0.47 
(Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 9.61 (s, 1H, NHTs), 8.19 (d, J = 7.3 Hz, 1H, HAr), 7.72 (d, J = 8.2, 0.8 Hz, 
2H, HAr), 7.53 (dd, J = 7.7, 1.5 Hz, 1H, HAr), 7.51-7.43 (m, 3H, Htolyl + HAr), 7.38-7.31 (m, 3H, HAr), 7.15 
(td, J = 7.6, 1.1 Hz, 1H, HAr), 7.09 (s, 1H, CH-N),  6.79 (d, J = 8.0 Hz, 2H, Htolyl), 3.81 (s, 3H, NCH3), 2.05 
(s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 190.8, 143.1, 138.5, 137.4, 137.2, 136.2, 132.1, 130.6, 130.3, 129.2, 127.4, 
127.0, 124.1, 124.0, 123.9, 123.1, 122.7, 115.8, 109.8, 33.7, 21.4. 
IR νmax 3216 (w), 2920 (w), 1595 (m), 1521 (s), 1487 (m), 1466 (s), 1396 (m), 1365 (s), 1334 (s), 1233 (s), 
1159 (s), 1126 (m), 1092 (m), 1073 (m), 925 (m), 869 (s), 814 (m), 747 (s). 
HRMS calculated for C23H20N2NaO3S+ [M+Na]+ 427.1087; found 427.1095. 
 
N-(2-(1-Methyl-1H-indole-3-carbonyl)phenyl)-4-nitrobenzenesulfonamide (8b) 
 
Following General Procedure E2, starting from N-(2-formylphenyl)4-
nitrobenzenesulfonamide 7b and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc/DCM 6:3:1) afforded the title 
compound 8b (52.0 mg, 0.119 mmol, 80% yield) or (280 mg, 0.643 mmol, 80% 
yield) as a yellow solid. mp 212-214 °C. Rf 0.67 (Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 9.46 (s, 1H, NHNs), 8.17 (d, J = 7.1 Hz, 1H, HAr), 7.77 (d, J = 8.1 Hz, 1H, 
HAr), 7.68 (d, J = 8.9 Hz, 2H, Hnosyl), 7.60 (d, J = 8.9 Hz, 2H, Hnosyl), 7.58-7.51 (m, 2H, HAr), 7.43-7.34 (m, 
2H, HAr), 7.33-7.27 (m, 2H, HAr), 6.97 (s, 1H, CH-N), 3.73 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 190.0, 149.2, 144.7, 138.3, 137.2, 135.5, 132.2, 132.1, 129.8, 128.7, 126.8, 
126.6, 125.8, 124.6, 123.7, 123.5, 122.6, 115.6, 110.2, 33.6. 
IR νmax 3105 (w), 2933 (w), 1737 (w), 1608 (m), 1595 (m), 1527 (s), 1466 (m), 1404 (m), 1367 (s), 1349 
(s), 1232 (m), 1164 (s), 874 (m), 856 (m), 763 (s), 757 (m), 739 (s), 712 (m). 
HRMS calculated for C22H17N3NaO5S+ [M+Na]+ 458.0781; found 458.0780. 
 
N-(2-(1-Methyl-1H-indole-3-carbonyl)phenyl)methanesulfonamide (8c) 
 
Following General Procedure E2, starting from N-(2-formylphenyl)4-
methylsulfonamide 7c and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 7:3) afforded the title compound 8c 
(42.6 mg, 0.130 mmol, 86% yield) as a white solid. mp 132-134 °C. Rf 0.41 
(Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 9.63 (s, 1H, NHMs), 8.37-8.31 (m, 1H, HAr), 7.79-7.75 (m, 2H, HAr), 7.55-
7.51 (m, 2H, CH-N + HAr), 7.41-7.34 (m, 3H, HAr), 7.22 (t, J = 7.6 Hz, 1H, HAr), 3.87 (s, 3H, NCH3), 2.97 
(s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 191.3, 138.6, 138.2, 137.8, 132.8, 131.6, 128.2, 127.2, 124.3, 123.5, 123.4, 
122.7, 121.0, 116.0, 110.2, 40.1, 34.0. 
IR νmax 3216 (br), 2933 (w), 1608 (m), 1521 (s), 1488 (s), 1464 (s), 1363 (s), 1327 (s), 1233 (s), 1149 (s), 
1127 (s), 1104 (m), 1074 (m), 969 (s), 924 (m), 868 (s), 744 (s). 
HRMS calculated for C17H16N2NaO3S+ [M+Na]+ 351.0774; found 351.0770. 
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N-(4-Chloro-2-(1-methyl-1H-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (8d) 
 
Following General Procedure E2, starting from N-(4-chloro-2-formylphenyl)4-
methylbenzenesulfonamide 7d and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 7:3) afforded the title compound 
8d (59.9 mg, 0.136 mmol, 91% yield) as a white solid. mp 193-195 °C. Rf 0.68 
(Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 9.36 (s, 1H, NHTs), 8.21-8.18 (m, 1H, HAr), 7.68 (d, J = 8.7 Hz, 1H, HAr), 
7.50-7.46 (m, 3H, Htolyl + HAr), 7.43 (dd, J = 8.7, 2.4 Hz, 1H, HAr), 7.40-7.33 (m, 3H, HAr), 7.08 (s, 1H, 
CH-N), 6.79 (d, J = 8.1 Hz, 2H, Htolyl), 3.83 (s, 3H, NCH3), 2.05 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 189.0, 143.3, 138.4, 137.5, 136.0, 135.6, 131.9, 131.8, 130.0, 129.8, 129.3, 
127.4, 126.9, 125.8, 124.3, 123.5, 122.7, 115.5, 109.9, 33.9, 21.4. 
IR νmax 3228 (m), 1608 (m), 1594 (m), 1523 (s), 1469 (m), 1396 (m), 1385 (m), 1362 (s), 1328 (s), 1233 
(m), 1160 (s), 1129 (m), 1090 (s), 878 (s), 814 (s), 750 (s), 715 (s). 
HRMS calculated for C23H19ClN2NaO3S+ [M+Na]+ 461.0697; found 461.0701. 
 
4-Methyl-N-(2-(1-methyl-1H-indole-3-carbonyl)thiophen-3-yl)benzenesulfonamide (8e) 
 
Following General Procedure E2, starting from N-(2-formylthiophen-3-yl)-4-
methylbenzenesulfonamide 7e and Me-indoleBX 5a, a purification by column 
chromatography on silica gel (Pentane/EtOAc 3:2) afforded the title compound 8e 
(55.5 mg, 0.135 mmol, 90% yield) as a yellow solid. mp 158-160 °C. Rf 0.50 
(Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 11.32 (s, 1H, NHTs), 8.36 (d, J = 5.9 Hz, 1H, HAr), 7.87 (s, 1H, CH-N), 7.78 
(d, J = 7.8 Hz, 2H, Htolyl), 7.47 (d, J = 5.4 Hz, 1H, HAr), 7.38 (d, J = 5.4 Hz, 1H, HAr), 7.34-7.29 (m, 3H, 
HAr), 7.20 (d, J = 7.8 Hz, 2H, Htolyl), 3.84 (s, 3H, NCH3), 2.32 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 182.9, 143.9, 137.3, 136.9, 135.0, 130.8, 129.8, 127.4, 127.2, 124.0, 122.9, 
122.7, 121.3, 119.2, 115.8, 109.9, 33.8, 21.6. One aromatic C is not resolved. 
IR νmax 3117 (w), 3087 (w), 1554 (s), 1515 (s), 1463 (s), 1399 (s), 1370 (s), 1344 (s), 1227 (s), 1152 (s), 
1087 (s), 862 (s), 815 (s), 748 (s). 
HRMS calculated for C21H19N2O3S2+ [M+H]+ 411.0832; found 411.0832. 
 
N-(2-(1-(But-3-en-1-yl)-1H-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (8f) 
 
Following General Procedure E2, starting from N-(2-formylphenyl)4-
methylbenzenesulfonamide 7a and butenyl-indoleBX 5d, a purification by column 
chromatography on silica gel (Pentane/EtOAc 7:3) afforded the title compound 8d 
(52.7 mg, 0.119 mmol, 79% yield) as a pale yellow solid. mp 50-52 °C. Rf 0.80 
(Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 9.74 (s, 1H, NHTs), 8.18 (d, J = 7.0 Hz, 1H, HAr), 7.73 (d, J = 8.2 Hz, 1H, 
HAr), 7.57-7.53 (m, 3H, Htolyl + HAr), 7.46 (td, J = 8.1, 1.5 Hz, 1H, HAr), 7.41-7.30 (m, 3H, HAr), 7.21 (s, 1H, 
CH-N), 7.14 (td, J = 7.6, 1.1 Hz, 1H, HAr), 6.87 (d, J = 8.0 Hz, 2H, Htolyl), 5.76 (ddt, J = 17.1, 10.3, 6.9 Hz, 
1H, CH=CH2), 5.15-5.05 (m, 2H, CH=CH2), 4.19 (t, J = 7.1 Hz, 2H, NCH2), 2.60 (q, J = 7.0 Hz, 2H, 
NCH2CH2), 2.08 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 191.1, 143.3, 137.6, 137.6, 136.7, 136.5, 133.7, 132.3, 130.9, 129.8, 
129.4, 127.5, 127.3, 124.1, 123.9, 123.3, 123.2, 123.0, 118.8, 116.0, 110.1, 46.8, 34.3, 21.5. 
IR νmax 3672 (w), 3222 (br), 2976 (m), 2914 (m), 1607 (m), 1599 (m), 1520 (s), 1486 (m), 1466 (m), 1394 
(s), 1377 (s), 1335 (m), 1158 (s), 1090 (s), 1048 (m), 922 (m), 868 (s), 735 (s). 
HRMS calculated for C26H25N2O3S+ [M+H]+ 445.1580; found 445.1576. 
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N-(2-(5-Bromo-1-methyl-1H-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (8g) 
 
Following General Procedure E2, starting from N-(2-formylphenyl)4-
methylbenzenesulfonamide 7a and Me-bromoindoleBX 5b, a purification by 
column chromatography on silica gel (Pentane/EtOAc 1:1) afforded the title 
compound 8e (59.3 mg, 0.123 mmol, 82% yield) as an off-white solid. mp 186-188 
°C. Rf 0.27 (Pentane/EtOAc 1:1). 
 
1H NMR (400 MHz, CDCl3) δ 9.55 (s, 1H, NHTs), 8.30 (d, J = 1.6 Hz, 1H, HAr), 7.72 (dd, J = 8.2, 0.8 
Hz, 1H, HAr), 7.53-7.43 (m, 5H, Htolyl + HAr), 7.22 (d, J = 8.5 Hz, 1H, HAr), 7.16 (td, J = 7.6, 1.1 Hz, 1H, 
HAr), 7.12 (s, 1H, CH-N), 6.85 (d, J = 8.0 Hz, 2H, Htolyl), 3.80 (s, 3H, NCH3), 2.07 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 190.6, 143.2, 138.8, 137.3, 136.3, 136.1, 132.4, 130.5, 129.8, 129.3, 128.5, 
127.4, 127.1, 125.3, 124.1, 124.0, 116.9, 115.3, 111.3, 33.9, 21.4. 
IR νmax 3222 (br), 2933 (m), 1607 (m), 1596 (s), 1525 (s), 1486 (m), 1460 (s), 1450 (m), 1390 (m), 1366 
(s), 1332 (s), 1232 (s), 1163 (s), 1090 (m), 877 (m), 803 (s), 763 (s), 719 (s). 
HRMS calculated for C23H2079BrN2O3S+ [M+H]+ 483.0373; found 483.0372. 
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6. Product modifications 
 
2-(1-Methyl-1H-indole-3-carbonyl)phenyl trifluoromethanesulfonate (9) 
 
 
 
6a (126 mg, 0.500 mmol, 1.00 equiv.) and pyridine (80 µL, 1.0 mmol, 2.0 equiv.) were solubilized in DCM 
(2.5 mL). Triflic anhydride (100 µL, 0.600 mmol, 1.20 equiv.) was added at 0 °C. The mixture was stirred 
1 h at rt and then quenched with H2O. The layers were separated and the aqueous layer was extracted three 
times with DCM (10 mL). The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. A purification by column chromatography on silica gel 
(Pentane/EtOAc 7:3) afford the title compound 9 (192 mg, 0.500 mmol, 100% yield) as a white solid. mp 
148-150 °C. Rf 0.66 (Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 8.40-8.33 (m, 1H, HAr), 7.64 (dd, J = 7.5, 1.8 Hz, 1H, HAr), 7.61-7.55 (m, 
1H, HAr), 7.50-7.45 (m, 1H, HAr), 7.42 (d, J = 8.3 Hz, 1H, HAr), 7.38-7.33 (m, 4H, CH-N + HAr), 3.83 (s, 
3H, NCH3). 19F NMR (376 MHz, CDCl3) δ -73.6. 13C NMR (101 MHz, CDCl3) δ 185.7, 146.5, 138.7, 
137.9, 135.0, 131.6, 130.6, 128.2, 126.7, 124.1, 123.3, 122.8, 122.5, 118.6 (q, J = 320 Hz), 116.4, 109.9, 
33.8. IR νmax 1620 (s), 1525 (m), 1466 (m), 1422 (s), 1369 (m), 1237 (m), 1215 (s), 1206 (s), 1144 (s), 1096 
(m), 1073 (m), 907 (s), 881 (m), 853 (s), 772 (s), 759 (s), 732 (m). HRMS calculated for C17H13F3NO4S+ 
[M+H]+ 384.0512; found 384.0507. 
 
[1,1'-Biphenyl]-2-yl(1-methyl-1H-indol-3-yl)methanone (10) 
 
 
 
9 (90.0 mg, 0.235 mmol, 1.00 equiv.), PhB(OH)2 (29.0 mg, 0.238 mmol, 1.00 equiv.), K2CO3 (64.9 mg, 
0.470 mmol, 2.00 equiv.) and Pd(PPh3)4 (8.1 mg, 7.0 µmol, 3 mol %) were solubilized in dioxane (1.0 mL)/ 
water (0.2 mL) previously degazed by bubbling N2. The mixture was stirred 12 h at 90 °C and then quenched 
with H2O. The layers were separated and the aqueous layer was extracted three times with EtOAc (10 mL). 
The combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. A purification by column chromatography on silica gel (Pentane/EtOAc 4:1) afforded the title 
compound 10 (65.2 mg, 0.209 mmol, 89% yield) as a white solid. mp 174-176 °C. Rf 0.80 (Pentane/EtOAc 
1:1). 
1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.2 Hz, 1H, HAr), 7.57-7.48 (m, 3H, HAr), 7.45-7.37 (m, 3H, 
HAr), 7.33-7.13 (m, 7H, CH-N + HAr), 3.70 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 192.5, 141.2, 
140.7, 140.3, 138.6, 137.6, 130.4, 129.7, 128.9, 128.5, 128.4, 127.3, 127.0, 126.7, 123.5, 122.7 (2C), 117.2, 
109.6, 33.5. IR νmax 3105 (w), 3050 (w), 3031 (w), 1620 (s), 1524 (s), 1463 (m), 1369 (s), 1228 (s), 1124 
(m), 1073 (m), 887 (m), 870 (m), 743 (s). HRMS calculated for C22H18NO+ [M+H]+ 312.1383; found 
312.1386. 
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(1-Methyl-1H-indol-3-yl)(phenyl)methanone (11) 
 
 
 
9 (38.3 mg, 0.100 mmol, 1.00 equiv.), Pd(OAc)2 (2.2 mg, 10 µmol, 0.10 equiv) and dppp (12.4 mg, 30.0 
µmol, 0.300 equiv) were solubilized in dioxane (1.0 mL) previously degazed by bubbling N2. Formic acid 
(15 µL, 0.40 mmol, 4.0 equiv.) and triethylamine (55 µL, 0.40 mmol, 4.0 equiv.) were added to the solution. 
The mixture was stirred 2 h at 90 °C and then quenched with H2O. The layers were separated and the aqueous 
layer was extracted three times with EtOAc (10 mL). The combined organic layers were washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. A purification by column chromatography on 
silica gel (Pentane/EtOAc 4:1) afforded the title compound 11 (22.9 mg, 97.0 µmol, 97% yield) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 8.48-8.41 (m, 1H, HAr), 7.81 (d, J = 7.0 Hz, 2H, HAr), 7.59-7.44 (m, 
4H, HAr), 7.39-7.32 (m, 3H, HAr), 3.83 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 191.0, 141.0, 138.0, 
137.6, 131.2, 128.8, 128.4, 127.3, 123.7, 122.8, 122.8, 115.7, 109.7, 33.7. Spectra data matched with the 
values reported in literature.17  
                                                   
17 Taylor, J. E.; Jones, M. D.; Williams, J. M. J.; Bull, S. D. Org. Lett. 2010, 12, 5740–5743. 
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6-Methyl-5-((4-methylphenyl)sulfonyl)-5,6-dihydro-11H-indolo[2,3b]quinolin-11-one (12a) 
 
 
 
Following a reported procedure,18 8a (36.4 mg, 90.0 µmol, 1.00 equiv.) and Cs2CO3 (58.7 mg, 180 µmol, 
2.00 equiv.) were suspended in ACN (9 mL). I2 (45.7 mg, 180 µmol, 2.00 equiv.) was added, the mixture 
was stirred 1 h at rt and then quenched with a saturated aqueous Na2S2O3 solution. The layers were separated 
and the aqueous layer was extracted three times with EtOAc (10 mL). The combined organic layers were 
washed with brine, dried over MgSO4 and concentrated under reduced pressure. A purification by column 
chromatography on silica gel (Pentane/EtOAc 4:1) afforded the title compound 12a (36.2 mg, 90.0 µmol, 
100% yield) as a white solid. mp 161-163 °C. Rf 0.85 (Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 7.7 Hz, 1H, HAr), 8.17 (d, J = 8.2 Hz, 1H, HAr), 7.99 (dd, J = 7.8, 
1.5 Hz, 1H, HAr), 7.60 (td, J = 8.3, 7.9, 1.6 Hz, 1H, HAr), 7.50 (d, J = 8.0 Hz, 1H, HAr), 7.48-7.36 (m, 3H, 
HAr), 6.91 (d, J = 8.2 Hz, 2H, HAr), 6.81 (d, J = 8.4 Hz, 2H, HAr), 4.10 (s, 3H, NCH3), 2.26 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 175.9, 146.0, 144.4, 139.2, 136.7, 131.1, 129.2, 128.9, 128.2, 127.6, 126.4, 
125.8, 124.6, 123.2, 122.6, 121.9, 110.3, 109.2, 33.3, 21.8. One carbon atom is not resolved. 
IR νmax 3056 (w), 1640 (m), 1596 (w), 1524 (w), 1486 (m), 1461 (m), 1448 (w), 1417 (w), 1370 (m), 1263 
(m), 1169 (m), 780 (m), 736 (s). 
HRMS calculated for C23H19N2O3S+ [M+H]+ 403.1111; found 403.1112. 
 
6-Methyl-5-((4-nitrophenyl)sulfonyl)-5,6-dihydro-11H-indolo[2,3b]quinolin-11-one (12b) 
 
 
 
Following the same procedure as described for 12a, starting from 8b (87.0 mg, 0.200 mmol, 1.00 equiv.), 
Cs2CO3 (130 mg, 0.400 mmol, 2.00 equiv.) and I2 (101 mg, 0.400 mmol, 2.00 equiv.). A purification by 
column chromatography on silica gel (Pentane/EtOAc 4:1) afforded the title compound 12b (77.0 mg, 0.178 
mmol, 89% yield) as a yellow solid. mp 187-189 °C. Rf 0.89 (Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 7.8 Hz, 1H, HAr), 8.17 (d, J = 7.9 Hz, 1H, HAr), 8.00 (dd, J = 
7.8, 1.6 Hz, 1H, HAr), 7.99-7.95 (m, 2H, HAr), 7.66 (td, J = 8.1, 1.6 Hz, 1H, HAr), 7.54-7.45 (m, 3H, HAr), 
7.42 (td, J = 7.6, 1.3 Hz, 1H, HAr), 7.15-7.09 (m, 2H, HAr), 4.11 (s, 3H, NCH3).  
13C NMR (101 MHz, CDCl3) δ 175.4, 151.0, 143.3, 138.3, 137.2, 136.7, 131.6, 131.1, 129.6, 128.4, 
126.9, 125.9, 125.2, 123.7, 123.6, 122.4, 122.1, 110.5, 109.3, 33.3. 
IR νmax 3105 (w), 3062 (w), 1646 (s), 1601 (m), 1532 (s), 1491 (s), 1461 (s), 1379 (m), 1350 (s), 1186 
(s), 1171 (s), 784 (s), 738 (s). 
HRMS calculated for C22H15N3NaO5S
+ [M+Na]+ 456.0625; found 456.0630. 
  
                                                   
18 Li, Y.-X.; Wang, H.-X.; Ali, S.; Xia, X.-F.; Liang, Y.-M. Chem. Commun. 2012, 48, 2343–2345. 
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6-Methyl-5,6-dihydro-11H-indolo[2,3b]quinolin-11-one (13) 
 
 
 
12b (65.0 mg, 0.150 mmol, 1.00 equiv.), K2CO3 (124 mg, 0.900 mmol, 6.00 equiv.) and benzenethiol (61 
µL, 0.60 mmol, 4.0 equiv.) were solubilized in DMF (1.5 mL). The mixture was stirred 2 h at 50 °C and 
then filtered over Celite with MeOH (20 mL). A purification by column chromatography on silica gel (DCM 
100% to DCM/MeOH 4:1) afforded the title compound 13 (32.7 mg, 0.132 mmol, 88% yield) as a white 
solid. mp > 350 °C. Rf 0.34 (DCM/MeOH 19:1). 
1H NMR (400 MHz, DMSO-d6) δ 12.33 (s, 1H, NH), 8.28 (d, J = 7.3 Hz, 1H, HAr), 8.21 (d, J = 7.4 Hz, 
1H, HAr), 7.82 (d, J = 8.2 Hz, 1H, HAr), 7.66 (t, J = 7.0 Hz, 1H, HAr), 7.53 (d, J = 7.9 Hz, 1H, HAr), 7.37-
7.28 (m, 2H, HAr), 7.24 (t, J = 7.2 Hz, 1H, HAr), 3.95 (s, 3H, NCH3). 
13C NMR (101 MHz, DMSO-d6) δ 172.0, 145.9, 138.5, 136.2, 130.8, 125.3, 123.6, 123.3, 122.6, 121.7, 
121.2, 120.0, 117.7, 109.1, 101.2, 29.3. 
IR νmax 2994 (br), 1639 (s), 1583 (s), 1535 (s), 1482 (s), 1465 (s), 740 (s). 
HRMS calculated for C16H13N2O
+ [M+H]+ 249.1022; found 249.1024. 
 
(2-Aminophenyl)(1-methyl-1H-indol-3-yl)methanone (14) 
 
 
 
8b (87.0 mg, 0.200 mmol, 1.00 equiv.), K2CO3 (166 mg, 1.20 mmol, 6.00 equiv.) and benzenethiol (82 µL, 
0.80 mmol, 4.00 equiv.) were solubilized in DMF (2 mL). The mixture was stirred overnight at 50 °C. The 
mixture was diluted with water (10 mL). The layers were separated and the aqueous layer was extracted 
three times with EtOAc (10 mL). The combined organic layers were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. A purification by column chromatography on silica gel 
(Pentane/EtOAc 4:1) afforded the title compound 14 (50 mg, 0.20 mmol, 100% yield) as a yellow solid. mp 
183-185 °C. Rf 0.72 (Pentane/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 8.37-8.31 (m, 1H, HAr), 7.64 (dd, J = 7.8, 1.5 Hz, 1H, HAr), 7.48 (s, 1H, 
CH-N), 7.39-7.31 (m, 3H, HAr), 7.30-7.24 (m, 1H, HAr), 6.76-6.68 (m, 2H, HAr), 5.45 (s, 2H, NH2), 3.81 (s, 
3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 192.4, 148.8, 137.5, 137.2, 132.5, 132.1, 127.4, 127.1, 123.5, 122.5, 122.5, 
116.8, 116.5, 116.1, 109.7, 33.5. 
IR νmax 3672 (br), 3475 (w), 3364 (w), 2976 (s), 2902 (s), 1610 (s), 1577 (m), 1521 (s), 1462 (m), 1394 (s), 
1367 (s), 1230 (s), 1075 (s), 1053 (s), 888 (s), 744 (s). 
HRMS calculated for C16H14N2NaO
+ [M+Na]+ 273.0998; found 273.0999.   
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7. Spectra of new compounds 
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